<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003122.pub2" GROUP_ID="DEMENTIA" ID="852100101810284876" MERGED_FROM="" MODIFIED="2008-06-05 15:15:58 +0200" MODIFIED_BY="Helen Collins" REVIEW_NO="111" REVMAN_SUB_VERSION="5.0.11" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2008-06-05 15:15:58 +0200" MODIFIED_BY="Helen Collins">
<TITLE>Hormone replacement therapy for cognitive function in postmenopausal women</TITLE>
<CONTACT MODIFIED="2008-06-05 15:15:58 +0200" MODIFIED_BY="Helen Collins"><PERSON ID="4773" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Lethaby</LAST_NAME><POSITION>Systematic reviewer </POSITION><EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Section of Epidemiology &amp; Biostatistics</DEPARTMENT><ORGANISATION>School of Population Health,University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599 ext 86333</PHONE_1><FAX_1>+64 9 373 7503</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-06-05 15:15:58 +0200" MODIFIED_BY="Helen Collins"><PERSON ID="4773" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Anne</FIRST_NAME><LAST_NAME>Lethaby</LAST_NAME><POSITION>Systematic reviewer </POSITION><EMAIL_1>a.lethaby@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Section of Epidemiology &amp; Biostatistics</DEPARTMENT><ORGANISATION>School of Population Health,University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599 ext 86333</PHONE_1><FAX_1>+64 9 373 7503</FAX_1></ADDRESS></PERSON><PERSON ID="13033" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Eva</FIRST_NAME><LAST_NAME>Hogervorst</LAST_NAME><POSITION>Research Scientist</POSITION><EMAIL_1>E.Hogervorst@lboro.ac.uk </EMAIL_1><ADDRESS><DEPARTMENT>Department of Human Sciences</DEPARTMENT><ORGANISATION>Loughborough University</ORGANISATION><CITY>Loughborough</CITY><ZIP>LE11 3TU</ZIP><REGION>Leicestershire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1509 223020</PHONE_1><FAX_1>+44 1509 223940</FAX_1></ADDRESS></PERSON><PERSON ID="8043" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Marcus</FIRST_NAME><LAST_NAME>Richards</LAST_NAME><POSITION>MRC Lead Scientist and Reader in Cognitive Epidemiology</POSITION><EMAIL_1>dmjd612@ucl.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>University College London Department of Epidemiology &amp; Public Health</DEPARTMENT><ORGANISATION/><ADDRESS_1>1-19 Torrington Place</ADDRESS_1><CITY>London</CITY><ZIP>WC1E 6BT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)20 7679 1737</PHONE_1><FAX_1>+44 (0)20 7813 0280</FAX_1></ADDRESS></PERSON><PERSON ID="9091C8D282E26AA200F0756DEE0FE93C" ROLE="AUTHOR"><FIRST_NAME>Amina</FIRST_NAME><LAST_NAME>Yesufu</LAST_NAME><EMAIL_1>a.yesufu@lboro.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Human Sciences</DEPARTMENT><ORGANISATION>Loughborough University</ORGANISATION><ADDRESS_1>Brockington Building</ADDRESS_1><ADDRESS_2>Asby Road </ADDRESS_2><CITY>Loughborough</CITY><ZIP>LE11 3TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01509 223013</PHONE_1><FAX_1>01509 223940</FAX_1></ADDRESS></PERSON><PERSON ID="13096" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Kristine</FIRST_NAME><LAST_NAME>Yaffe</LAST_NAME><SUFFIX>M.D.</SUFFIX><EMAIL_1>kyaffe@itsa.ucsf.edu</EMAIL_1><ADDRESS><DEPARTMENT>Psychiatry, Neurology and Epidemiology</DEPARTMENT><ORGANISATION>University of California, San Francisco</ORGANISATION><ADDRESS_1>4150 Clement Street</ADDRESS_1><CITY>San Francisco</CITY><ZIP>94121</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-06-05 13:08:10 +0100" MODIFIED_BY="Helen Collins">
<UP_TO_DATE>
<DATE DAY="10" MONTH="9" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="3" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="11" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-06-05 14:07:51 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="5" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-06-05 14:07:51 +0100" MODIFIED_BY="Helen Collins">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-06-05 14:07:51 +0100" MODIFIED_BY="Helen Collins">
<DATE DAY="10" MONTH="9" YEAR="2007"/>
<DESCRIPTION>
<P>The following changes have been made to the review since it was published in 2002:<BR/>(1) Search updated to March 2006<BR/>(2) Results updated for the following six included trials:<BR/>- Almeida 2006<BR/>- Dunkin 2005<BR/>- Resnick 2006<BR/>- Shumaker 2003<BR/>- Shumaker 2004<BR/>- Yaffe 2006<BR/>Four other trials that met the inclusion criteria are in the 'Studies Awaiting Assessment' section of the review because the reviewers are awaiting suitable data.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>OPTIMA, Department of Pharmacology, University of Oxford</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Bristol-Myers Squibb</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-06-05 13:56:01 +0100" MODIFIED_BY="Helen Collins">
<SUMMARY MODIFIED="2008-06-05 13:14:14 +0100" MODIFIED_BY="Helen Collins">
<TITLE MODIFIED="2008-06-05 13:14:14 +0100" MODIFIED_BY="Helen Collins">There is good evidence that estrogen or combined estrogen and progestagen therapy does not protect against a decline in overall cognitive functioning of older postmenopausal women with normal intellectual ability</TITLE>
<SUMMARY_BODY>
<P>Animal studies (performed both in the laboratory and on living animals) suggest that estrogen alone might protect the brain as women get older. After the menopause, levels of estrogens decline in women and estrogen therapy has been claimed to maintain or enhance cognitive function in postmenopausal women. This review found no evidence of a benefit of any types of estrogen on overall cognitive functioning in older postmenopausal women when given either as short term or longer term (up to five years) therapy. There was also no evidence of a beneficial effect of combined estrogen and progestagen therapy overall. There was insufficient evidence to determine whether any type of hormone replacement therapy had beneficial or harmful effects on specific types of cognitive ability, such as verbal or visual memory. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>As estrogens have been found in animal models to be associated with the maintenance and protection of brain structures, it is biologically plausible that maintaining high levels of estrogens in postmenopausal women by medication could be protective against cognitive decline. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To investigate the effect of ERT (estrogens only) or HRT (estrogens combined with a progestagen) in comparison with placebo in RCTs on cognitive function in postmenopausal women. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The CDCIG Specialized Register was searched 7 March 2006. Additional searches were made of MEDLINE (1966-2006/02); EMBASE (1985-2006/02); PsycINFO (1967-2006/02) and CINAHL (1982-2006/01).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All double-blind RCTs trials of the effect of ERT or HRT on cognitive function over a treatment period of at least two weeks in postmenopausal women.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Selection of studies, assessment of quality and extraction of data were undertaken independently by three reviewers with disagreements resolved by discussion.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>In total, 24 trials were included, but only 16 (10,114 women) had analysable data. Meta-analyses showed no effects of either ERT or HRT on prevention of cognitive impairment after five and four years of treatment, respectively (odds ratio 1.34, 95% CI 0.95 to 1.9; odds ratio 1.05, 95% CI 0.72 to 1.54 respectively) (trend favouring control in both instances). Analyses assessing the effects of treatment over time found that both ERT and HRT did not maintain or improve cognitive function and may even adversely affect this outcome (WMD = -0.45, 95% CI -0.99 to 0.09; WMD = -0.16, 95% CI -0.58 to 0.26, respectively at maximum follow up). Negative effects were found for ERT after one year and HRT after three and four years of therapy. Results from smaller trials assessing effects on individual cognitive domains mostly reported no evidence of benefit.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is good evidence that both ERT and HRT do not prevent cognitive decline in older postmenopausal women when given as short term or longer term (up to five years) therapy. It is not known whether either specific types of ERT or HRT have specific effects in subgroups of women, although there was evidence that combined hormone therapy in similarly aged women was associated with a decrement in a number of verbal memory tests and a small improvement in a test of figural memory. There is insufficient evidence to determine whether subgroups of women using specific types of hormone therapy could benefit from treatment. It remains to be determined whether factors such as younger age (&lt; 60 years of age), type of menopause (surgical or natural) and type of treatment (type of estrogen with or without a progestagen), mode of delivery (transdermal, oral or intramuscular) and dosage have positive effects at a clinically relevant level. In addition, whether the absence or presence of menopausal symptoms can modify treatment effects should be investigated in more detail. Large RCTs currently underway in the USA may be able to provide answers to these uncertainties by the year 2010. In the meantime, based on the available evidence, ERT or HRT cannot be recommended for overall cognitive improvement or maintenance in older postmenopausal women without cognitive impairment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-06-05 13:56:01 +0100" MODIFIED_BY="Helen Collins">
<BACKGROUND MODIFIED="2008-06-05 13:56:01 +0100" MODIFIED_BY="Helen Collins">
<P>Nearly all cognitive functions decline, on average, with age, but there is a large variability which ranges from "successful" aging to dementia (<LINK REF="REF-Huppert-1997" TYPE="REFERENCE">Huppert 1997</LINK>). The determinants of this variability are uncertain but elderly women seem to have a higher risk of developing Alzheimer's disease (AD) than elderly men (<LINK REF="REF-Launer-1999" TYPE="REFERENCE">Launer 1999</LINK>). While this may be because they reach an older age and aging is a risk factor for AD, the age-specific incidence of AD is also higher in women than in men (<LINK REF="REF-Fratiglioni-2000" TYPE="REFERENCE">Fratiglioni 2000</LINK>). It has been suggested that steroid hormone deficiencies in elderly women may play a role in this difference.</P>
<P>Estrogens (UK spelling oestrogens) are steroid hormones produced in women by their ovaries. The estrogen-producing cells become depleted at menopause and postmenopausal women have much lower estrogen levels than men. In men, and in women after the menopause, the main source of estrogens is from conversion of circulating androgen steroid hormone precursors. In women, the main source of androgen steroids are the ovaries (theca cells) and the adrenal cortex, whereas in men it is the testes. Estrogens have an important role in the female reproductive cycle, but animal and in vivo cell studies have suggested that estrogens can also protect brain structures, including those related to memory, such as the hippocampus and the cholinergic basal forebrain (<LINK REF="REF-McEwen-1997" TYPE="REFERENCE">McEwen 1997</LINK>). A variety of mechanisms appear to be involved in this process, including anti-amyloidogenic effects, antioxidant effects, dendritic sprouting and effects on various neurotransmitters involved in cognitive function (<LINK REF="REF-McEwen-1997" TYPE="REFERENCE">McEwen 1997</LINK>; <LINK REF="REF-Silva-2001" TYPE="REFERENCE">Silva 2001</LINK>).</P>
<P>It is possible that maintaining high levels of estrogens in women by means of estrogen replacement therapy (ERT) or combined therapy with estrogens and progestagens (hormone replacement therapy - HRT) could be protective against cognitive decline and the development of AD or other dementia syndromes (see <LINK REF="REF-Hogervorst-2002-b" TYPE="REFERENCE">Hogervorst 2002 b</LINK>). Postmenopausal ERT or HRT is usually prescribed to treat menopausal symptoms, such as hot flashes (UK hot flushes) and night sweats, or as treatment or prevention for osteoporosis. Prior to 2002, several large observational studies suggested that ERT or HRT also had a role in the prevention of cerebrovascular disease. However, several recent randomized trials have shown that the harms outweigh the benefits of HRT or ERT; an increased association of HRT with CVD, stroke, VTE and breast cancer and an increased association of ERT with stroke and breast cancer have been reported (<LINK REF="REF-Farquhar-2005" TYPE="REFERENCE">Farquhar 2005</LINK>). Many of these trials had large sample sizes with adequate power, long follow up, clinically relevant endpoints and included largely older women with natural menopause. Thus, HRT or ERT currently only have a role only in the short term treatment of intolerable hot flashes or night sweats in women close to the menopause and these medications are no longer considered first line for the prevention of osteoporosis. For hysterectomized postmenopausal women, replacement therapy is usually given as ERT, but HRT is prescribed for women with intact uteri to reduce the risk of endometrial hypertrophy or cancer.</P>
<P>Several observational studies have found that women who have used HRT or ERT after their menopause have better cognitive function than controls (<LINK REF="REF-Hogervorst-2000" TYPE="REFERENCE">Hogervorst 2000</LINK>; <LINK REF="REF-Yaffe-1998-a" TYPE="REFERENCE">Yaffe 1998 a</LINK>), but, as was the case in the assessment of the relationship between HRT/ERT and cerebrovascular disease, observational studies are subject to bias (<LINK REF="REF-Barrett_x002d_Connor-1991" TYPE="REFERENCE">Barrett-Connor 1991</LINK>). Women who choose to use HRT or ERT after the menopause have in general higher education, healthier lifestyles and are healthier before using ERT or HRT than women who do not (<LINK REF="REF-Matthews-1996" TYPE="REFERENCE">Matthews 1996</LINK>). Taking ERT or HRT may therefore be associated with a healthier lifestyle in general which in turn could be associated with better cognitive function. In addition, despite estrogen's biologically plausible mechanisms for protecting the aging brain, most reviews have concluded that the human studies have substantial methodological problems and, as a consequence, results have been conflicting (<LINK REF="REF-Hogervorst-2000" TYPE="REFERENCE">Hogervorst 2000</LINK>; <LINK REF="REF-Yaffe-1998-a" TYPE="REFERENCE">Yaffe 1998 a</LINK>). A recent review (<LINK REF="REF-Maki-2006" TYPE="REFERENCE">Maki 2006</LINK>) has suggested that the effects could be differential in younger as opposed to older postmenopausal women. This review has presented results separately for women aged less than 65 years and greater than 65 years. The authors found good evidence that long-term hormone treatment in older women did not improve cognitive functioning. They suggested that there could be a benefit of estrogen alone in younger postmenopausal women but the included trials were unconvincing becase of their small size and short duration.</P>
<P>Prior to this update, most studies evaluating the effects of ERT or HRT on cognitive abilities in postmenopausal women were of short duration and many had numerous methodological flaws, giving rise to uncertain conclusions. The publication of a number of large studies with adequate periods of follow-up and clinically relevant endpoints has prompted this update.</P>
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> for a full list of abbreviations used in this review.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of therapy consisting of estrogens alone (ERT) or in combination with a progestagen (HRT) on cognitive function of postmenopausal women. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-06-05 13:15:30 +0100" MODIFIED_BY="Helen Collins">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All double-blind randomized placebo-controlled trials (RCTs) in which ERT or HRT was administered to postmenopausal women without dementia for at least two weeks and cognitive function was measured were eligible for inclusion. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Healthy women of any age who had undergone natural or surgical menopause. Women were considered postmenopausal if they had not menstruated for more than 12 months.<BR/> </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Interventions containing estrogens alone (ERT) or combined with a progestagen (HRT) at any dose, any dosing schedule and any mode of administration - oral, subdermal, transdermal or intravenous - were eligible for inclusion. </P>
<P>The most commonly used ERTs are: <BR/>CEE = conjugated equine estrogens (always orally in dosages 0.625 or 1.25 mg, contains E1-S = estrone sulphate)<BR/>E2 = estradiol (usually given transdermally (0.1 to 0.005 mg: <LINK REF="STD-Polo_x002d_Kantola-1998" TYPE="STUDY">Polo-Kantola 1998</LINK>) or as a bolus injection of 10 mg/month (<LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK>; <LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>) or sometimes orally (1 to 2 mg/daily, <LINK REF="STD-Fedor_x002d_Freyberg-1977" TYPE="STUDY">Fedor-Freyberg 1977</LINK>). <BR/>Estrogens may be given in combination with a progestagen which is usually MPA (= medroxyprogesterone acetate) or P (= progesterone) (<LINK REF="STD-Goebel-1995" TYPE="STUDY">Goebel 1995</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcome of interest is cognitive function (measured either by validated neuropsychological tests or by strict protocols):<BR/>The following outcomes were relevant:</P>
<P>A. Tests of overall global cognitive function:<BR/>(1) CAMCOG <BR/>(2) Folstein Mini-Mental State Examination<BR/>(3) Modified Mini-Mental State Examination</P>
<P>B. Cognitive impairment (defined and assessed by strict protocol)</P>
<P>C. Specific tests for individual cognitive domains have been categorized as follows: <BR/>(1) Verbal Memory and Language Tests (Paired Associate Learning and Paragraph Recall or Logical Memory from the Wechsler Memory Scale or WMS; Word List Memory; Word List Recall; California Verbal Learning Test; verbal Fluency with animals, vegetables, fruits or letters; Boston Naming Test; PMA Vocabulary Test) <BR/>(2) Visuospatial (Visual Retention tests or VRT from the WMS; the Benton Visual Retention Test; The Figure of Rey; Block Design; Visuospatial Memory Test) <BR/>(3) Speed Tests, Attention and Manual Dexterity Semantic Memory (Trail Making Test, part A or TMT-A; Digit Symbol Substitution Test or DSST; reaction time (RT) tests; finger tapping; Grooved Pegboard Test; Stroop Tasks A and B) <BR/>(4) Mental Rotation tests and Accuracy (Clerical Speed and Accuracy, Letter Cancellation tests etc.)<BR/>(5) Executive function (Wisconsin Card Sorting Tests; Wechsler Adult Intelligence Scale (picture arrangement); Tower of London; Stroop Tests (interference); TMT-B (Trails B); COWAT; Digits Backward)<BR/>Some of the tests have multiple functions and may span other categories to the one in which they have been placed.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 7 March 2006 using the search terms: HRT, ERT, ORT, PORT, Oestrogen*, estrogen*, progesteron*, progestagen, estradiol.</P>
<P>The Specialized Register at that time contained records from the following databases:<BR/>
</P>
<UL>
<LI>CENTRAL: July 2005 (issue 3);</LI>
<LI>MEDLINE: 1966 to 2005/08, week 2;</LI>
<LI>EMBASE: 1980 to 2005/08, week 2;</LI>
<LI>PsycINFO: 1887 to 2005/07;</LI>
<LI>CINAHL: 1982 to 2004/07;</LI>
<LI>SIGLE (Grey Literature in Europe): 1980 to 2004/06;</LI>
<LI>ISTP (Index to Scientific and Technical Proceedings): to May 2000;</LI>
<LI>INSIDE (BL database of Conference Proceedings and Journals): to June 2000;</LI>
<LI>Aslib Index to Theses (UK and Ireland theses): 1970 to March 2003;</LI>
<LI>Dissertation Abstract (USA): 1861 to March 2003;</LI>
<LI>http://clinicalstudies.info.nih.gov/;</LI>
<LI>National Research Register (issue 3/2005)</LI>
<LI>ClinicalTrials.gov: last searched 1 March 2006;</LI>
<LI>LILACS:Latin American and Caribbean Health Science Literature: last searched April 2003</LI>
<LI>http://www.forestclinicaltrials.com/: last searched 1 September 2005</LI>
<LI>ClinicalStudyResults.org: last searched 1 September 2005</LI>
<LI>http://www.lillytrials.com/index.shtml: last searched 28 August 2005</LI>
<LI>ISRCTN Register: last searched 1 September 2005</LI>
<LI>IPFMA Clinical trials Register: www.ifpma.org/clinicaltrials.html: last searched September 2005</LI>
</UL>
<P>
<BR/>The search strategies used to identify relevant records in MEDLINE, EMBASE, PsycInfo, CINAHL and LILACS can be found in the Group's module.</P>
<P>In addition MEDLINE (1966-2006/02); EMBASE (1985-2006/02); PsycINFO (1967-2006/02) and CINAHL (1982-2006/01) were searched as the CDCIG Register does not contain all trials with healthy volunteers. </P>
<P>MEDLINE<BR/>#1 "Hormone-Replacement-Therapy"/ all subheadings <BR/>#2 HRT or ERT or ORT or PORT or oestrogen* or estrogen* or progesteron* <BR/>#3 estradiol* or progestagen* <BR/>#4 #1 or #2 or #3 <BR/>#5 cognit* or QOL or "quality of life" or mood* or memor* <BR/>#6 #4 and #5 <BR/>#7 #6 and (post-menopausal or "post menopausal") <BR/>#8 #7 and (random* or double-blind* or placebo*) </P>
<P>EMBASE<BR/>#1 explode "Hormone-Replacement-Therapy"/ all subheadings <BR/>#2 HRT or ERT or ORT or PORT or oestrogen* or estrogen* or progesteron* <BR/>#3 estradiol* or progestagen* <BR/>#4 #1 or #2 or #3 <BR/>#5 cognit* or QOL or "quality of life" or mood* or memor* <BR/>#6 #4 and #5 <BR/>#7 #6 and (post-menopausal or "post menopausal") <BR/>#8 #7 and (random* or double-blind* or placebo*) </P>
<P>PsycINFO<BR/>#1 "Hormone-Therapy" in MJ,MN <BR/>#2 HRT or ERT or ORT or PORT or oestrogen* or estrogen* or progesteron* <BR/>#3 cognit* or QOL or "quality of life" or mood* or memor* <BR/>#4 (#1 or #2) and #3 <BR/>#5 #4 and (post-menopausal or "post menopausal") </P>
<P>CINAHL<BR/>#1 "Hormone-Replacement-Therapy"/ all subheadings <BR/>#2 HRT or ERT or ORT or PORT or oestrogen* or estrogen* or progesteron* <BR/>#3 estradiol* or progestagen* <BR/>#4 #1 or #2 or #3 <BR/>#5 cognit* or QOL or "quality of life" or mood* or memor* <BR/>#6 #4 and #5 <BR/>#7 #6 and (post-menopausal or "post menopausal") <BR/>#8 #7 and (random* or double-blind* or placebo*) <BR/> <BR/>Studies were eligible for inclusion if they were published in the English language.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-06-05 13:15:30 +0100" MODIFIED_BY="Helen Collins">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies </HEADING>
<P>Abstracts of the references retrieved by the search were read by three reviewers (EH, AL and KY) in order to discard those that were clearly not eligible for inclusion (such as those that were not randomized, placebo-controlled or double blinded, or where cognitive function was not measured). The reviewers studied the full text of the remaining references and independently selected studies for inclusion. Any disparity in the resulting lists was resolved by discussion with all reviewers in order to arrive at the final list of included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>Two reviewers assessed the quality of the studies according to the Cochrane Collaboration guidelines which focus on the concealment of allocation of treatment.</P>
<P>Category A (adequate) is where the report describes allocation of treatment by: (1) some form of centralized randomized scheme, such as having to provide details of an enrolled participant to an office by phone to receive the treatment group allocation; (2) some form of randomization scheme controlled by a pharmacy; (3) numbered or coded containers, such as in a pharmaceutical trial in which capsules from identical-looking numbered bottles are administrated sequentially to enrolled participants; (4) an on-site or coded computer system, given that the allocations were in a locked, unreadable file that could be accessed only after inputting the characteristics of an enrolled participant; or (5) if assignment envelopes were used, the report should at least specify that they were sequentially numbered, sealed, and opaque; (6) other combinations of described elements of the process that provides assurance of adequate concealment.</P>
<P>Category B (unclear) is where the report does not include a description of how allocation to randomized groups is concealed and authors do not respond to requests for this information. Examples include: (1) assignment envelopes without description of adequate safeguards; (2) use of a "list" or "table"; (3) flip of a coin; (4) a trial in which the description suggests adequate concealment but other features are suspicious - for example, markedly unequal control and treatment groups, a trial described as random but unable to obtain further details.</P>
<P>Category C (inadequate) is where the report describes allocation of treatment by: (1) alternation; (2) reference to case record numbers, dates of birth, day of week, or any other such approach; (3) any allocation procedure that is entirely transparent before assignment, such as an open list of random numbers or assignments.</P>
<P>Empirical research has shown that lack of adequate allocation concealment is associated with bias. Trials with unclear concealment measures have been shown liable to yield more pronounced estimates of treatment effects than trials that have taken adequate measures to conceal allocation schedules, albeit to a less extent than inadequately concealed trials.</P>
<P>Other aspects of the trial quality (methodology, statistics) were assessed and included in an additional table of quality features.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data collection</HEADING>
<P>Data for the meta-analyses were based on reported summary statistics for each study. To test cognitive change after treatment, the main outcome of interest was the change from baseline to final assessment (mean difference in performance and SD of the mean difference in performance). The baseline assessment was defined as the last available assessment prior to randomization. In the case of large trials with long follow-up, the difference between the treatment and control groups was extracted at follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>Clinical heterogenity was assessed through evaluation of potential differences between participants, interventions and outcomes within each study. Where studies appeared to be clinically comparable, data were pooled in meta-analyses. Odds ratios using the fixed effects model were obtained for dichotomous data (rates of cognitive impairment) and Weighted Mean Differences (WMD) using the fixed effects model were obtained for continuous data (differences between groups in the psychometric test scores). In some cases, the mean difference was calculated as the difference between post-treatment and baseline performance. The standard deviation (SD) of this difference was calculated as the square root of the variance of the baseline plus the variance of the final assessment where the SD of the difference was not reported. For the large trials with long follow-up, the treatment effect and standard error were calculated. The WMD was used as the outcome measure where trials were measuring identical outcomes. The Standardized Mean Difference (SMD) with a random effects model was calculated where trials were not strictly comparable; either different tests within the same cognitive domain, different types of participants or different interventions.</P>
<P>Statistical heterogeneity was assessed by inspecting the scatter in the data points on the graphs and the overlap in their confidence intervals and, more formally, by checking the I square quantity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). This quantity describes the percentage of total variation across studies that is due to heterogeneity rather than chance. Interpretation of a given degree of heterogeneity will differ according to whether the estimates show the same direction of effect but it was planned to tentatively assign descriptions of low, moderate and high heterogeneity to I<SUP>2</SUP> values of 0 to 25%, 26 to 74% and 75 to 100% respectively. A priori, it was planned to look at the possible contribution of differences in trial design to any meta-analyses with an I<SUP>2</SUP> value of 50% or more.</P>
<P>The null hypothesis tested was that, for any of the above outcomes, treatment had no effect compared with placebo.</P>
<P>The following sensitivity analyses were planned to examine the stability of the results. Analyses were to be repeated excluding studies which differed in certain ways:<BR/>(1) Estrogen therapy alone versus combined estrogen plus progestagen therapy<BR/>(2) Surgically menopausal women versus women who had natural menopause<BR/>(3) Early postmenopausal women (&lt;60 years) versus older postmenopausal women (&gt;60 years)<BR/>(4) Studies with adequate allocation concealment versus studies without adequate allocation concealment<BR/>(5) Studies with short follow up (&lt;6 months) versus studies with longer follow up (&gt;6 months)<BR/>However, there were insufficient trials assessing the same types of cognitive tests, except in one case, to conduct these analyses.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-06-05 13:24:17 +0100" MODIFIED_BY="Helen Collins">
<STUDY_DESCRIPTION MODIFIED="2008-06-05 13:16:45 +0100" MODIFIED_BY="Helen Collins">
<P>Twenty four trials were identified that met the inclusion criteria for the review. Six earlier trials (<LINK REF="STD-Ditkoff-1991" TYPE="STUDY">Ditkoff 1991</LINK>; <LINK REF="STD-Fedor_x002d_Freyberg-1977" TYPE="STUDY">Fedor-Freyberg 1977</LINK>; <LINK REF="STD-Goebel-1995" TYPE="STUDY">Goebel 1995</LINK>; <LINK REF="STD-Polo_x002d_Kantola-1998" TYPE="STUDY">Polo-Kantola 1998</LINK>; <LINK REF="STD-Shaywitz-1999" TYPE="STUDY">Shaywitz 1999</LINK>; <LINK REF="STD-Vanhulle-1976" TYPE="STUDY">Vanhulle 1976</LINK>) had insufficient outcome data for analysis. We had tried to contact all the authors, but could not reach the above, save for Fedor-Freyberg and Polo-Kantola. However, neither of these could provide us with the necessary data for analysis. The authors of a further two trials (<LINK REF="STD-Dumas-2006" TYPE="STUDY">Dumas 2006</LINK>; <LINK REF="STD-Schiff-2005" TYPE="STUDY">Schiff 2005</LINK>) have been contacted for clarification of outcome data and are in the 'Studies awaiting assessment' section of the review. The reviewers included data from the tables of <LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Binder-2001" TYPE="STUDY">Binder 2001</LINK>; <LINK REF="STD-Dunkin-2005" TYPE="STUDY">Dunkin 2005</LINK>; <LINK REF="STD-Duka-2000" TYPE="STUDY">Duka 2000</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK>; <LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK>; <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>; <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK> and data from the graphs of <LINK REF="STD-Janowsky-2000" TYPE="STUDY">Janowsky 2000</LINK>; <LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK> and <LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>. For only three (<LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK>; <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK>) the data of the mean difference and the SD of that difference were available. For all the others, these had to be calculated using the method described above or where there was long follow up and natural attrition, the treatment effect and standard error were calculated. The descriptive details that follows is a summary of only the 16 trials that had data suitable for analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">Study design</HEADING>
<P>Fifteen of the 16 studies were of parallel group design. In the crossover study that was included (<LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK>) we used data from only the first treatment period which is comparable to the parallel group design. Treatment lasted from two weeks (<LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK>) to 5.4 years (<LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>). Five studies had a duration of greater than one year.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Screening and selection</HEADING>
<P>The total number of participants randomized in the trials ranged from 12 to 4532. Prior to 2002, most of the trials included fewer than 100 women. The three largest trials (<LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>) included 4532, 2947 and 1416 women respectively. In total, 10,114 postmenopausal women have had assessments of their cognitive function in randomized trials. A wide variety in the type of subjects were included. While some studies had rigorous health screenings, others had few exclusion criteria. In addition, one study included only postmenopausal women with sleep difficulties (<LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK>), while others investigated more heterogeneous groups of women from the community (e.g. <LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Dunkin-2005" TYPE="STUDY">Dunkin 2005</LINK>). Some studies included a mix of naturally and surgically menopausal women but others investigated relatively young women who were tested prior to and immediately after surgically induced menopause (e.g. <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK>; <LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>). There was insufficient information in the studies to do split analyses on these aspects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Age and control for confounding factors (education, mood) </HEADING>
<P>One study included women of a wide age-range (<LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK>: 29 to 68 years) without controlling for age-effects in the analyses. Eight trials, including all of the large studies, only included older postmenopausal women (&gt; 60 years in one study, &gt; 65 years in four studies, &gt; 70 years in one study, &gt; 75 years in one study and 'several years after the menopause' in one study). Eleven studies (<LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Binder-2001" TYPE="STUDY">Binder 2001</LINK>; <LINK REF="STD-Duka-2000" TYPE="STUDY">Duka 2000</LINK>; <LINK REF="STD-Dunkin-2005" TYPE="STUDY">Dunkin 2005</LINK>; <LINK REF="STD-Janowsky-2000" TYPE="STUDY">Janowsky 2000</LINK>; <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>; <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK>) had comparable age and education status between randomized groups at baseline. For four studies there was no information on education so separate analyses based on this variable could not be undertaken. Only a few studies ensured that mood was taken into account (<LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Dunkin-2005" TYPE="STUDY">Dunkin 2005</LINK>; <LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK>; <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK>); they either demonstrated that groups were comparable in terms of rate of depression at baseline or they controlled for mood in their analyses.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interventions</HEADING>
<P>The mode, administration, dose and type of hormone therapy varied widely.</P>
<P>Three RCTs prescribed unopposed oral CEE to postmenopausal women. The other studies used transdermal (four), intramuscular (three) or oral (two) estradiol (E2) treatments. In addition, one RCT prescribed estrone (E1). Hence, most (nine) studies employed an estradiol (E2) preparation. All studies from the group led by Sherwin (<LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK>; <LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>) gave a bolus injection of 10 mg of estradiol once monthly, which was shown to give very high blood levels of E2 (e.g. 1837 SD 11 pmol/L). In contrast, other studies used a transdermal patch containing E2 (<LINK REF="STD-Duka-2000" TYPE="STUDY">Duka 2000</LINK>; <LINK REF="STD-Dunkin-2005" TYPE="STUDY">Dunkin 2005</LINK>; <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK>) which gave much lower blood levels of E2. In addition, while all of the transdermal studies supplied the same amount of E2 in the transdermal patch, namely 0.1 mg/24 h, the average E2 levels reached in the women investigated by <LINK REF="STD-Duka-2000" TYPE="STUDY">Duka 2000</LINK> were higher (average 220 pmol/L) than those of <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK> (average 124 pmol/L). One study (<LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>) used a relatively high escalating dosage of unopposed estradiol in elderly women to minimize side effects. Two studies (<LINK REF="STD-Binder-2001" TYPE="STUDY">Binder 2001</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>) added a progestagen (MPA) for women who had not undergone hysterectomy but no separate analyses were done for cases with versus without MPA. One study (<LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK>) compared the effects of estradiol alone with a new progestagen regimen (Dienogest). Two large studies assessed the effects of combined oral CEE + MPA on cognitive function in women with an intact uterus (<LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>).</P>
<P>Compliance checks were done using serum or plasma estrogen levels in 10 studies, five did a pill count and one study did not have a compliance check (<LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cognitive assessments</HEADING>
<P>Most of the studies assessed cognitive function using specific cognitive tests for different cognitive domains but few of the studies used similar cognitive tests, so making the pooling of data difficult. In some instances, different aspects of the same tests were used (only immediate or delayed recall, or reaction time but not accuracy), or different versions. Analyses were split for tests of verbal (e.g. Paragraph Recall, Paired Associate test, Guild Memory test, Fluency) and visual (e.g. Visual Retention test) memory and for those which tested other aspects of cognitive function, such as speed of information processing (TMT-A/B, Stroop), mental rotations, accuracy of performance, manual dexterity and motor speed and executive function.</P>
<P>Five studies (<LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK>) used more global measures to assess cognitive function: either CAMCOG (Cambridge Cognitive Examination for Mental Disorders of the Elderly) (one study), Folstein Mini Mental State Examination (one study) or 3MSE (Modified Mini-Mental State Examination) all of which are highly correlated. Two of these studies (<LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>) also compared the rates of "mild cognitive impairment" between groups after follow up of four or five years. Mild cognitive impairment was distinguished from "probable dementia" in the study and was defined according to a strict protocol with four phases of ascertainment. The diagnosis was based on the <I>Diagnostic and Statistical Manual of Mental Disorders</I>, 4th edition (DSM-IV) criteria and included poor performance (10th or lower percentile based on CERAD norms) on at least one CERAD test, a report of some functional impairment (but not sufficient to interfere with basic activities of daily living) from the designated informant, no evidence of a psychiatric disorder or medical condition that could account for the decline in cognitive function and an absence of adjudicated dementia.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Statistics</HEADING>
<P>Some studies (e.g. <LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK>; <LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK>) made separate comparisons for treated subjects and the subjects using placebo, or made separate analyses for baseline and post-treatment effects (<LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK>; <LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>). Without adjustment, this strategy enhances the risk of chance findings due to multiple comparisons. For some of the larger studies, with long follow up, there was attrition of participants and so the change score could not be used because the number of participants at baseline differed from the number of participants at later follow-up. Where this occurred, the treatment effect at follow-up was calculated by the authors and the data entered using a inverse variance method, where the weight given to each study is chosen to be the inverse of the variance of the effect estimate. This method minimizes the uncertainty of the pooled effect estimate.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-06-05 13:17:31 +0100" MODIFIED_BY="Helen Collins">
<P>In general, some methodological problems could be found in most of the earlier smaller studies (<LINK REF="REF-Hogervorst-2000" TYPE="REFERENCE">Hogervorst 2000</LINK>; <LINK REF="REF-Yaffe-1998-a" TYPE="REFERENCE">Yaffe 1998 a</LINK>). The quality features of all of the included studies with available data are summarized in Additional Table 1, Quality of Included Studies (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Blinding is not included in this table as all trials were required to have at least double blinding before they could be considered eligible for inclusion.</P>
<SUBSECTION>
<HEADING LEVEL="3">Randomization method</HEADING>
<P>Seven studies provided full details of their randomization procedure, two provided incomplete details and seven did not describe the randomization procedure.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Seven studies provided evidence of adequate allocation concealment and received a score of A. For the remaining trials, it was not clear whether there were processes in place to conceal the allocation to randomized groups; nine studies received an allocation concealment score of B.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Attrition</HEADING>
<P>The proportion of dropouts varied widely. Some small trials were short term and had no or very few dropouts. Five trials (<LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Binder-2001" TYPE="STUDY">Binder 2001</LINK>; <LINK REF="STD-Dunkin-2005" TYPE="STUDY">Dunkin 2005</LINK>; <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK>) had more than 10% of randomized participants not included in the analyses. <LINK REF="STD-Dunkin-2005" TYPE="STUDY">Dunkin 2005</LINK> lost 33% and 36% in the ERT and placebo groups respectively after randomization.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intention to treat analyses</HEADING>
<P>Two trials (<LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>) had true intention to treat analysis and also provided completer's analyses of outcomes. The two largest studies (<LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>) undertook true intention to treat analysis for the primary outcome of mild cognitive impairment but only modified intention to treat analyses for the scores on the 3MSE test (inclusion in the analyses of the participants in the groups to which they had been initially randomized but no imputation for participants who dropped out during follow up). Two studies (<LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK>) claimed that they had performed intention to treat analyses but there was no correction made for those who dropped out during follow up. Another small trial (<LINK REF="STD-Duka-2000" TYPE="STUDY">Duka 2000</LINK>) did not provide any information in the publication about dropouts and intention to treat analysis is thus presumed. The remaining studies, n = 9, did not report intention to treat analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Power calculation for sample size</HEADING>
<P>The five largest studies (<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK>) undertook power calculations for sample size. The remaining studies did not report whether this had been undertaken but given their size, it is unlikely.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-06-05 13:24:17 +0100" MODIFIED_BY="Helen Collins">
<P>Twenty four studies met inclusion criteria, but data of six RCTs (<LINK REF="STD-Ditkoff-1991" TYPE="STUDY">Ditkoff 1991</LINK>; <LINK REF="STD-Fedor_x002d_Freyberg-1977" TYPE="STUDY">Fedor-Freyberg 1977</LINK>; <LINK REF="STD-Goebel-1995" TYPE="STUDY">Goebel 1995</LINK>; <LINK REF="STD-Polo_x002d_Kantola-1998" TYPE="STUDY">Polo-Kantola 1998</LINK>; <LINK REF="STD-Shaywitz-1999" TYPE="STUDY">Shaywitz 1999</LINK>; <LINK REF="STD-Vanhulle-1976" TYPE="STUDY">Vanhulle 1976</LINK>) were not available for analysis and two other studies are waiting assessment. The following results are thus based on data from the remaining 16 studies. The findings of the studies without suitable data for analysis are also discussed, where relevant. All studies had been published in peer-reviewed journals.</P>
<SUBSECTION>
<HEADING LEVEL="3">Overall measures of cognitive function</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Global cognition scores</HEADING>
<P>There was no evidence of a difference in the scores on the global cognition test, CAMCOG after 20 weeks of E2 oral or placebo (Forest plot 1-1). However, the large WHIMS trial of combined estrogen plus progestagen therapy found significant differences in the 3MSE scores in favour of placebo at three and four years follow up (P value unadjusted) (WMD = -0.36, 95% CI -0.61 to -0.11; WMD = -0.52, 95% CI -0.81 to -0.23 respectively) (Forest plot 1-2). The other summary estimates at different follow up times did not differ significantly between treatment groups, although estimates were consistently to the left of the line of no effect, favouring placebo. Two trials (<LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>; <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK>) assessed 3MSE scores after one and two years of unopposed estrogen therapy and one trial assessed this outcome at longer follow up (<LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>). Women in the estrogen groups had significantly lower 3MSE scores at one year follow up (almost identical estimates in both trials) (Forest plot 1-3). There was no evidence of a significant difference between 3MSE scores at two, three, four, five or six years follow up, although estimates were consistently to the left of the line of no effect, favouring placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mild cognitive impairment</HEADING>
<P>There was no evidence of a difference in the rates of mild cognitive impairment either after a mean of five years with unopposed oral estrogen therapy or after a mean of four years with combined estrogen plus progestagen therapy (Forest plot 2-1).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Measures of specific cognitive domains</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Verbal memory and language tests</HEADING>
<P>Only two studies, by the same group (<LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>), had employed the same type of participants (surgically menopausal women), the same treatment (a 10 mg E2 bolus injection intramuscularly monthly for 2 to 3 months), the same tests and the same outcome measures. In these studies, the Paired Associate learning immediate recall was significantly in favour of treatment (SMD = 1.09, 95% CI 0.12 to 2.07) but no significant effects were found between groups in a small trial using transdermal E2 with participants with unknown type of menopause (Forest plot 3-1). The same test with a different scoring system for the immediate recall showed no evidence of an effect after nine months of CEE + MPA in older women (SMD = 0.3, 95% CI -0.27 to 0.88) but continued to show a statistically significant difference in the two smaller trials with surgically menopausal women (SMD = 1.02, 95% CI 0.19 to 1.85) (Forest plot 3-2). However, the delayed recall of the Paired Associate test did not reach significance after treatment with 10 mg E2 i.m./month for two months in relatively young surgically menopausal women, in the older women who were treated with CEE + MPA for nine months or in the women treated with E2 transdermal (Forest plot 3-3). The Paragraph recall (immediate and delayed recall) also showed no overall significant effect after 2 to 3 months of 10 mg E2 i.m./month in the relatively young surgically menopausal women (Forest plots 3-5 and 3-6). The study by <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK> had used a different Paired Associates test (with only six instead of 10 word pairs) and the study by <LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK>(*) had employed a different test for "associative verbal memory". Results of treatment with E2 + P oral for two months or E2 transdermal for two weeks were non-significant on both tests (Forest plot 3-4).</P>
<P>None of the other verbal memory or language tests used in the other studies showed evidence of an effect of treatment (Forest plots 3-7, 3-8, 3-9, 3-10, 3-11, 3-12, 3-13, 3-14, 3-15). There was no evidence of an effect on semantic memory (verbal Fluency), word list recall tests, Wechsler Memory Scale tests, Boston Naming Test or PMA Vocabulary after two weeks E2 transdermal; or after nine months of CEE; or on short-term memory (Digit Span forward) after 2 to 3 months of 10 mg E2 i.m./month; or on episodic memory (Guild memory test) after six months of piperazine E1. The trials included in these comparisons used various doses and modes of administration of estrogen, except for one small trial that used CEE + MPA (<LINK REF="STD-Binder-2001" TYPE="STUDY">Binder 2001</LINK>), and different durations of follow up.</P>
<P>However, some significant differences were found between groups in a larger trial of combined estrogen and progestagen therapy (CEE + MPA) after 4 to 5 years of therapy (<LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>) (Forest plot 3-16). In this study, women treated with HRT had significantly lower scores on a number of word list recall tests (CVLT total, CVLT short delay and CVLT long delay) (WMD = -0.52, 95% CI -.091, to -0.13; WMD = -0.24, 95% CI -0.44 to -0.04; WMD = -0.23, 95% CI -0.43 to -0.03 respectively). There were no significant differences found between the scores on the other verbal memory or language tests assessed in this trial: PMA vocabulary or verbal fluency.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Visual memory tests</HEADING>
<P>There was no evidence for an overall effect of treatment on different tests of visuospatial memory using SMD with a random-effects model (Forest plot 4-1). Only one of the studies employing a number of different regimens of estrogen (10 mg E2 i.m. monthly for 2 to 3 months, E2 transdermal for 2 to 10 weeks, E2 oral for 2 to 4 months, CEE oral for one month or low E transdermal for two years) showed evidence of a significant effect. In the <LINK REF="STD-Almeida-2006" TYPE="STUDY">Almeida 2006</LINK> trial, women randomized to E2 oral had a significantly higher mean score for the visual memory for faces test than those randomized to placebo. Overall, there was no significant heterogeneity between studies (I<SUP>2</SUP> = 13.8%) which suggests that it was reasonable to pool the studies. A number of other studies had employed visual memory tests (<LINK REF="STD-Fedor_x002d_Freyberg-1977" TYPE="STUDY">Fedor-Freyberg 1977</LINK>; <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Polo_x002d_Kantola-1998" TYPE="STUDY">Polo-Kantola 1998</LINK>; <LINK REF="STD-Vanhulle-1976" TYPE="STUDY">Vanhulle 1976</LINK>) but did not have data available for the meta-analyses. However, none of the studies, except <LINK REF="STD-Fedor_x002d_Freyberg-1977" TYPE="STUDY">Fedor-Freyberg 1977</LINK>, reported evidence for an effect of HRT on visual memory functions.</P>
<P>However, a significant but small difference on the Benton Visual Retention Test was found in the WHISCA trial comparing combined estrogen plus progestagen therapy (CEE + MPA) with placebo after 4 to 5 years follow up (Forest plot 4-2). A difference of -0.27 (95% CI -0.49 to -0.05) errors per year was reported between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Speed tests, attention and manual dexterity</HEADING>
<P>There was no evidence of an effect of nine months of CEE + MPA on simple speed of information processing (TMT-A, SMD=-0.42, 95% CI -1.0 to 0.15) (Forest plot 5-1). There was also no evidence of a significant difference in any of the other individual speed or attention tests or in the overall computed estimates for subgroups of tests with unopposed estrogen or combined therapy over variable follow up times (Forest plots 5-2, 5-3, 5-4, 5-5). In addition, most of the other studies with data not available for analysis also did not report any evidence for differences between HRT and placebo on measures of speed of information processing (<LINK REF="STD-Ditkoff-1991" TYPE="STUDY">Ditkoff 1991</LINK>; <LINK REF="STD-Goebel-1995" TYPE="STUDY">Goebel 1995</LINK>; <LINK REF="STD-Polo_x002d_Kantola-1998" TYPE="STUDY">Polo-Kantola 1998</LINK> but see <LINK REF="STD-Fedor_x002d_Freyberg-1977" TYPE="STUDY">Fedor-Freyberg 1977</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mental rotations and accuracy</HEADING>
<P>There was no significant effect on mental rotation test aspects (time to complete or number correct) after 2 to 3 weeks of E2 transdermal or after one year of CEE + MPA (Forest plots 7-1, 7-2, 7-3).<BR/>There was also no significant effect on accuracy as measured with Letter Cancellation after nine months of CEE + MPA or as measured with random number generation after three weeks of E2 transdermal (Forest plots 8-2, 8-3). However, again a highly significant effect was seen on the Clerical Speed and Accuracy test after three months of 10 mg E2 i.m. monthly in relatively young surgically menopausal women (WMD = 6.0, 95% CI 4.72 to 7.28) (Forest plot 8-1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Executive function</HEADING>
<P>The cognitive tests that assessed executive function included Wisconsin Card Sorting Test (categories, perserverative responses, % conceptual level responses), Wechsler Adult Intelligence Scale (picture arrangement), Tower of London, abstract reasoning, Trails B and the Stroop Interference Time and Errors tests. There was a significantly better performance after three months of 10 mg E2 i.m. monthly in relatively young surgically menopausal women on an abstract reasoning test (WMD = 6.80, 95% CI 5.52 to 8.08) (Forest plot 9-6). There was no evidence of a significant effect of any of the regimens (3 to 10 weeks or 1 to 2 years of E2 transdermal) on any of the other tests (Forest plots 9-1, 9-2, 9-3, 9-4, 9-5, 9-7, 9-8, 9-9, 9-10).</P>
<P>*For the <LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK> study, we compared only the E2+P versus placebo regimen only (see also the visual memory tests) as the E2 treatment was never shown to be significant compared with placebo.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-06-05 13:25:17 +0100" MODIFIED_BY="Helen Collins">
<P>Previous animal studies, epidemiologic observational studies and clinical trial data have suggested that estrogen therapy could protect against cognitive aging, particularly verbal memory, in healthy postmenopausal women (<LINK REF="REF-Sherwin-2003" TYPE="REFERENCE">Sherwin 2003</LINK>). There is good evidence from the studies in this review that cognitive abilities in older postmenopausal women (&gt; 65 years), as measured by global cognition tests, are not improved or maintained, and may even be adversely affected by hormone therapy, either unopposed estrogen or combined estrogen plus progestagen. In particular, significant declines in scores on the 3MSE test, a measure of global cognition function, were found for older postmenopausal women on combined CEE + MPA after three and four years and after one year of unopposed estrogen (4532 and 2947 women respectively). Rates of mild cognitive impairment were also not reduced when women are treated with hormone therapy. The two WHIMS trials, one with ERT and the other with HRT, both found similar effects on 3MSE scores, although women in the two trials differed according to many factors at baseline, including cognitive function. The effects also appeared to be consistent across numerous subgroups. However, baseline 3MSE score was associated with differential treatment effects. In both the ERT and HRT WHIMS trials, among women whose baseline scores exceeded 95 at baseline, the reduction in scores over the follow up of the trials did not differ statistically from zero. Women with relatively low baseline cognitive function (as defined by scores below the cutpoints that were defined according to education) had larger decreases in their 3MSE scores over time. These findings strongly suggest that hormone therapy, either ERT or HRT, should not be initiated in older postmenopausal women for the purpose of protecting cognitive function.</P>
<P>The 3MSE scale is a reliable and valid measure of global cognitive function but may be too coarse an instrument to adequately detect benefits or harms in specific cognitive domains, such as verbal memory. There was large variation in the other included studies in this review in the individual tests used, the design and size of the included studies, the participants (menopausal symptoms, age, type of menopause) and/or the treatment (type of hormone regimen, mode of administration, dose and duration). The question remains whether it is possible to tease out more specific effects of various types of hormone therapy on individual cognitive domains in specific subgroups of postmenopausal women.</P>
<P>Results from the trials assessing effects on individual cognitive domains showed no clear pattern. In summary, the meta-analyses showed a significant beneficial effect of 10 mg E2 i.m./month for 2 to 3 months in relatively young surgically menopausal women on only one aspect of a test of verbal memory (Paired Associate learning immediate recall) (two trials with a total of 31 women), on a test of abstract reasoning (one trial, 20 women) and a test of speed and accuracy (one trial, 20 women). A significant benefit was found for women on E2 oral for 20 weeks in their scores on a specific visual memory test, the Visual Memory for Faces test, but there was no difference overall when all visuospatial tests were combined. Treatment with CEE + MPA only showed a beneficial effect on one test of complex information processing (TMT-B) after nine months, which was not reported by the authors (one trial, 52 women) but this was not found in two other studies assessing this test. A deleterious effect after 4 to 5 years of combined CEE plus MPA in older postmenopausal women was found on a number of verbal memory tests (CVLT total and CVLT short and long delay). By contrast, a small beneficial effect after the same regimen was found for a test of short-term figural memory and visuoconstructional abilities (1416 women). Significant declines in scores on the 3MSE test, a measure of global cognition function, were also found for older postmenopausal women on combined CEE + MPA after three and four years and after one year of unopposed estrogen (4532 and 2947 women respectively). Many studies did not find any evidence of effects of treatment on verbal and visual memory tests, simple and complex speed of information processing, accuracy and executive function, but most of these studies had fewer than 100 participants and were likely to be underpowered.</P>
<P>Given that this review has found no benefit of either ERT or HRT for cognitive functioning overall, it has not been possible to determine whether the significant results found in some tests of individual cognitive domains are due to bias from methological shortcomings in the studies or to other factors such as the type of test used, type of participants, type of intervention or duration of follow up.</P>
<SUBSECTION>
<HEADING LEVEL="2">Type of individual tests</HEADING>
<P>In general, verbal memory has been considered to be most susceptible to the effects of estrogens (<LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>). However, there was only one memory subtest, the immediate Paired Associates test (but not the delayed recall) of the Wechsler Memory Scale, which showed a significant beneficial effect of estrogen therapy. By contrast, a larger study found a deleterious effect of HRT on tests of verbal memory, the California Verbal Learning Test (total, short and long delay). This finding was not reported for other smaller trials with a shorter duration of therapy. There was no evidence of a significant difference on any of the other verbal memory or language tests. The verbal memory tests that were not affected by HRT may have been conceptually different from the Paragraph and Paired Associates test or the CVLT tests and were probably slightly more difficult.</P>
<P>No significant differences were reported between groups for any of the visual memory tests, except for a small benefit for women randomized to CEE + MPA on the Benton Visual Retention Test (BVLT), a test of short-term figural memory and visuoconstructional abilities. It is not clear whether this represents a clinically important benefit. Other smaller trials assessing this test did not find a significant difference between groups.</P>
<P>Of the speeded tests, there was no evidence of a difference between treatment and control groups except for one small study. <LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK> reported significant beneficial effects for women on estrogen therapy compared to placebo on a test of clerical speed and accuracy.</P>
<P>There was no evidence of a significant difference in any of the tests measuring executive function, except for a significant benefit for one small study measuring abstract reasoning (<LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Subjects-screening and selection</HEADING>
<P>There was a wide variation in the type of participants included. One of the studies that investigated asymptomatic women (<LINK REF="STD-Ditkoff-1991" TYPE="STUDY">Ditkoff 1991</LINK>) did not report any effects of treatment and others (<LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>; <LINK REF="STD-Shumaker-2003" TYPE="STUDY">Shumaker 2003</LINK>; <LINK REF="STD-Shumaker-2004" TYPE="STUDY">Shumaker 2004</LINK>) found deleterious effects of hormone treatment. This raises the issue of whether the reduction in menopausal or climacteric symptoms is responsible for the effects of estrogen on cognitive function (see <LINK REF="REF-LeBlanc-2001" TYPE="REFERENCE">LeBlanc 2001</LINK>). <LINK REF="STD-Ditkoff-1991" TYPE="STUDY">Ditkoff 1991</LINK> used two tests which were not found to be sensitive to the effects of estrogen overall (Digit Span and DSST, a speed test). In addition, studies that directly tested this hypothesis (e.g. <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK>) did not find that cognitive effects were mediated through an alleviation in depression or improved sleep. However, <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK> did report a significant correlation between the reduction in hot flushes and performance on the immediate recall of the Paired Associate learning test, the only verbal memory test which showed a significant overall effect of treatment, which would be in favour of the 'symptom reduction causes cognition improvement' hypothesis. In line with this, <LINK REF="STD-Fedor_x002d_Freyberg-1977" TYPE="STUDY">Fedor-Freyberg 1977</LINK> who reported a large improvement on several measures of speed of performance, had included only women who were highly symptomatic</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Age, education and type of menopause of participants</HEADING>
<P>Some studies included women of a wide age-range (e.g. <LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK>: 29 to 68 years; <LINK REF="STD-Shaywitz-1999" TYPE="STUDY">Shaywitz 1999</LINK>: 33 to 61 years). The age differences between and within studies make comparison difficult as many of the tests are sensitive to the effects of aging. In fact, both studies did not find any effects which may have been caused by the large age-range, obscuring smaller effects of HRT.</P>
<P>It has not been possible in this review to answer the recent suggestion that there may be a critical window in the early postmenopause where treatment with estrogen therapy may protect against cognitive decline (<LINK REF="REF-Henderson-2004" TYPE="REFERENCE">Henderson 2004</LINK>; <LINK REF="REF-Sherwin-2003" TYPE="REFERENCE">Sherwin 2003</LINK>). The studies by Sherwin's group (<LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>; <LINK REF="STD-Sherwin-1988" TYPE="STUDY">Sherwin 1988</LINK>) all included relatively young (on average 47 years of age) women who had just undergone surgical menopause, suggesting that there may be only a limited window of time in which effects of HRT on cognitive function are apparent. Compatible with this interpretation is the observation that RCTs investigating much older women (<LINK REF="STD-Binder-2001" TYPE="STUDY">Binder 2001</LINK>; <LINK REF="STD-Goebel-1995" TYPE="STUDY">Goebel 1995</LINK>) found no evidence of benefit from treatment. However, studies including relatively young women (<LINK REF="STD-Shaywitz-1999" TYPE="STUDY">Shaywitz 1999</LINK>: 51 years of age, <LINK REF="STD-Polo_x002d_Kantola-1998" TYPE="STUDY">Polo-Kantola 1998</LINK>: 56 years of age) also found no evidence of positive effects on cognitive function. Possibly, no effects were found because these groups had all included a mixed group of natural and surgical menopausal women. According to some studies, a surgical menopause at a younger age accelerates cognitive aging (<LINK REF="REF-Nappi-1999" TYPE="REFERENCE">Nappi 1999</LINK>) and estrogen could perhaps prevent this.<BR/>Epidemiological studies also suggest that the effect of estrogen may be stronger in women with less education (<LINK REF="REF-Hogervorst-2000" TYPE="REFERENCE">Hogervorst 2000</LINK>). However, education of participants was not always given and we could not control for differential effects of treatment on participants with a low education. In general, age, type of menopause, education and depression have rarely been controlled for in the analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Treatment</HEADING>
<P>The studies that found positive effects on the immediate Paired Associates, the abstract reasoning and accuracy test were all from one group. Their subjects were given bolus injections of E2 i.m. per month which gave very high plasma levels of E2 (&gt; 1800 pmol/L <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>). In comparison, <LINK REF="STD-Wolf-1999" TYPE="STUDY">Wolf 1999</LINK> had given their subjects a transdermal patch of E2 that gave an overall low plasma E2 level (one tenth of those reached in the Sherwin studies employing a bolus injection). Interestingly, Wolf et al.'s post hoc analyses showed that the women who were treated and had higher plasma E2 levels (&gt; 106 pmol/L) had a better immediate and delayed Paired Associates performance than the women who were also treated but had lower E2 levels. <LINK REF="STD-Polo_x002d_Kantola-1998" TYPE="STUDY">Polo-Kantola 1998</LINK> also used a transdermal E2 patch (but with varying dosages) and no effect of treatment or the level of E2 was seen on cognitive functions. <LINK REF="STD-Duka-2000" TYPE="STUDY">Duka 2000</LINK> used a transdermal patch of E2 but their effects seemed to be largely explained by baseline differences. <LINK REF="STD-Yaffe-2006" TYPE="STUDY">Yaffe 2006</LINK> used a very low dose of transdermal estrogen (delivering 0.014 mg of estradiol per day) and reported no change in cognitive function. Thus, possibly the type of administration (transdermal patch versus intramuscular injections) and the E2 level reached determined the effect size.</P>
<P>In addition, the type of estrogen could be important. Inspection of the table of included studies show that those which used CEE, the most widely prescribed estrogen, either did not show any positive result as reported by the authors (see effect of TMT-B) or suggested potential harm (in global cognitive scores). The study by <LINK REF="STD-Hackman-1977" TYPE="STUDY">Hackman 1977</LINK> employed an estrone (E1) treatment and there was only a weak trend in the Guild Memory test in favour of treatment. E1 has less receptor affinity than E2 and could thus be expected to be less biologically active. In a very early study (<LINK REF="STD-Vanhulle-1976" TYPE="STUDY">Vanhulle 1976</LINK>) estriol (E3) was employed which has an even lower receptor affinity than E1. In this study, only very few and small effects were reported on vigilance and concentration.</P>
<P>Longitudinal studies that have assessed estrogen levels are in line with this theory. <LINK REF="REF-Yaffe-2000" TYPE="REFERENCE">Yaffe 2000</LINK> found that bioavailable E2 was associated with a slower decrement in the MMSE performance over time. However, <LINK REF="REF-Yaffe-1998-b" TYPE="REFERENCE">Yaffe 1998 b</LINK> also showed that high levels of E1 had detrimental effects on some speed measures over time. No distinction was made here between natural and surgical menopause, and age at menopause was not taken into account in the analyses. However, consistent with the discussion on different regimens, it is possible that different types of estrogens have different or even counteractive effects. This hypothesis remains to be tested; the review contains insufficient evidence to determine whether different types of estrogen have differential effects on cognition.</P>
<P>Another important questions is whether adding a progestagen is detrimental. This has often been postulated, since animal studies have shown that progestagens can counteract several of the actions of estrogens (on monoaminergic neurotransmitter systems and possibly on the vascular system (<LINK REF="REF-Hogervorst-2000" TYPE="REFERENCE">Hogervorst 2000</LINK>). A progestagen is added in HRT for women who have not been hysterectomized to reduce the risk of endometrial hyperplasia. Five studies (<LINK REF="STD-Binder-2001" TYPE="STUDY">Binder 2001</LINK>; <LINK REF="STD-Goebel-1995" TYPE="STUDY">Goebel 1995</LINK>; <LINK REF="STD-Greenspan-2005" TYPE="STUDY">Greenspan 2005</LINK>; <LINK REF="STD-Linzmayer-2001" TYPE="STUDY">Linzmayer 2001</LINK>; <LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK>) used a combined regimen (for two of these, the data was not analysed separately from women having unopposed estrogen). <LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK> reported that a combined regimen was associated with worsening scores for verbal memory tests and a small benefit for a test of figural memory when compared with placebo. The other trials did not find any effects of HRT on cognitive function but all of these, except for one, had fewer than 100 participants and are likely to be underpowered. It was not possible to determine in these trials whether age of the participants had an effect on the results. All but one of the trials were conducted with older women. Duration of therapy could explain the differences between the trials; the <LINK REF="STD-Resnick-2006" TYPE="STUDY">Resnick 2006</LINK> trial investigated effects after four or five years of therapy. There was insufficient evidence to determine whether different types of progestagen have differential effects on cognition.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Heterogeneity and sensitivity analyses</HEADING>
<P>There was no significant statistical heterogeneity (I<SUP>2</SUP> &gt; 50%) in any of the analyses. There were insufficient trials to undertake the planned sensitivity analyses, except in two cases.</P>
<P>(1) The results of three trials were pooled to assess effects of ERT/HRT on paired associate learning (immediate recall, with different scoring methods) (comparison 1/2). When the two trials with inadequate allocation concealment were excluded from the meta-analysis, the effects of hormone treatment were no longer significantly different from placebo.</P>
<P>(2) It is not clear whether some of the participants in two of the included studies in this review are identical, although they have been analysed separately (<LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>; <LINK REF="STD-Phillips-1992" TYPE="STUDY">Phillips 1992</LINK>). The authors are the same in both studies and the intervention and outcomes are identical. When the smaller of these studies is excluded in a sensitivity analysis (<LINK REF="STD-Sherwin-1990" TYPE="STUDY">Sherwin 1990</LINK>) (Forest plots 3-1 and 3-2), there is no longer a significant effect of ERT on the Paired Associate Learning test results (immediate recall).</P>
<P>This calls into question the suggestion that ERT may have a differential effect on a particular domain of cognitive function in specific types of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Summary</HEADING>
<P>It is clear that ERT or HRT does not protect against cognitive aging in older postmenopausal women, as represented by their scores on global cognition tests. The 3MSE test has good sensitivity and specificity for the detection of mild cognitive impairment (<LINK REF="REF-Bland-2001" TYPE="REFERENCE">Bland 2001</LINK>) and thus provides an overall indication of whether hormones protect against cognitive decline. Moreover, the findings in the same trials that both ERT or HRT increase the risk of probable dementia and do not prevent mild cognitive impairment supports the conclusion that older postmenopausal women should not use hormones to attenuate cognitive decline as they age. We have not been able to determine, because of insufficient randomized data, whether any type of hormone regimen has more specific effects on individual domains of cognition or whether different subgroups of women are more susceptible to the harmful or beneficial effects of hormones. There is an indication that HRT causes decrements in some verbal memory tests and a small but significant benefit for a particular figural memory test when given for an average of four years. In addition, It has been considered possible that the effect of unopposed estrogen is very specific and that there may be a critical period for benefit (<LINK REF="REF-Henderson-2004" TYPE="REFERENCE">Henderson 2004</LINK>; <LINK REF="REF-Maki-2005" TYPE="REFERENCE">Maki 2005</LINK>; <LINK REF="REF-Maki-2006" TYPE="REFERENCE">Maki 2006</LINK>; <LINK REF="REF-Sherwin-2003" TYPE="REFERENCE">Sherwin 2003</LINK>), notably symptomatic and recently menopausal women. This review suggests that surgically menopausal women of a relatively young age who are given bolus injections of E2 could benefit. However, the trials showing the benefit in this subgroup had low methodological quality scores and the findings could be due to chance (type 1 error).</P>
<P>Some of the unanswered questions from this review should be answered within the next few years. Results from the ERT arm of the WHISCA trial should be reported within the next year. Currently, two large prospective randomized placebo-controlled studies are in progress in the USA (PREPARE and KRONOS). The PREPARE trial (Preventing Postmenopausal Memory Loss and Alzheimers with Replacement Estrogens) no longer has an active treatment arm but is still following up participants. The KRONOS trial is assessing the effects of combined treatment on cognitive endpoints as secondary outcomes in women randomized within three years of the menopause over four years and is expected to report results in 2010. Results from the ERT arm of the WHISCA trial are currently being analysed. The WISDOM-COG trial (Women's International Study of long Duration estrogen after Menopause - Cognition) was prematurely terminated in 2002 after WHI results were released. By 2010, some of the unanswered questions about the effects of hormones on cognition may have been clarified. In the meantime, older postmenopausal women should not initiate hormone therapy to prevent cognitive decline.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-06-05 13:31:04 +0100" MODIFIED_BY="Helen Collins">
<IMPLICATIONS_PRACTICE>
<P>There is good evidence that both ERT and HRT do not prevent cognitive decline in older postmenopausal women. It is not known whether specific types of ERT or HRT have effects in subgroups of women, although there was evidence that combined hormone therapy (CEE + MPA) in similarly aged women was associated with a decrement in a number of verbal memory tests and a small improvement in a test of figural memory. There is insufficient evidence to determine whether subgroups of women using specific types of hormone therapy could benefit from treatment. Based on the available evidence, ERT or HRT cannot be recommended for cognitive improvement or maintenance in healthy postmenopausal women.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-06-05 13:31:04 +0100" MODIFIED_BY="Helen Collins">
<P>We need to await the results of the ongoing large RCTs to answer the questions raised in the discussion, which included the potential modifying effect on estrogen effects by factors such as age, surgical or natural menopause and menopausal symptoms in maintaining the cognitive functions of healthy postmenopausal women.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Marc Budge of OPTIMA.<BR/>Lindsay Stead, consumer editor.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-06-05 13:31:10 +0100" MODIFIED_BY="Helen Collins">
<P>-AL took on the update of the review in March 2006: all correspondence, all aspects of the review.</P>
<P>-EH became co-author in March 2006; previously main reviewer, correspondent, all aspects of review<BR/>-KY search for trials, extraction of data, interpretation data analyses, updating review<BR/>-MR search for trials, extraction of data, interpretation data analyses,<BR/>updating review<BR/>-FAH drafting review versions, selection of trials, interpretation data analyses; she withdrew as co-author in March 2006 when Anne Lethaby took over as main author.<BR/>-AY extracted data for the 2006 update.</P>
<P>-Contact editor: Leon Flicker.</P>
<P>-Consumer editor: Lindsay Stead.</P>
<P>-This review has been peer reviewed by two peer reviewers in 2007.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-06-05 14:11:28 +0100" MODIFIED_BY="Helen Collins">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Almeida-2006" NAME="Almeida 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almeida OP, Lautenschlager NT, Vasikaran S, Leedman P, Gelavis A, Flicker L</AU>
<TI>A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life</TI>
<SO>Neurobiology of Aging</SO>
<YR>2006</YR>
<VL>27</VL>
<PG>141-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Binder-2001" NAME="Binder 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM</AU>
<TI>Effects of HRT on cognitive performance in elderly women</TI>
<SO>Maturitas</SO>
<YR>2001</YR>
<VL>38</VL>
<NO>2</NO>
<PG>137-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ditkoff-1991" NAME="Ditkoff 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ditkoff EC, Crary, WG, Cristo M, Lobo RA</AU>
<TI>Estrogen improves psychological function in asymptomatic postmenopausal women</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>78</VL>
<PG>991-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duka-2000" NAME="Duka 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duka T, Tasker R, McGowan JF</AU>
<TI>The effects of 3-week estrogen hormone replacement on cognition in elderly healthy females</TI>
<SO>Psychopharmacology</SO>
<YR>2000</YR>
<VL>149</VL>
<PG>129-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunkin-2005" NAME="Dunkin 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunkin J, Rasgon N, Wagner Steh K, David S, Altshuler L, Rapkin A</AU>
<TI>Reproductive events modify the effects of estrogen replacement therapy on cognition in healthy postmenopausal women</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>3</NO>
<PG>284-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fedor_x002d_Freyberg-1977" NAME="Fedor-Freyberg 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fedor-Freyberg P</AU>
<TI>The influence of estrogens on the well-being and mental performance on the climacteric and postmenopausal women</TI>
<SO>Acta Obstetrics Gynecology Scandinavia</SO>
<YR>1977</YR>
<VL>64</VL>
<PG>12-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goebel-1995" NAME="Goebel 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goebel JA, Birge SJ, Price SC, Hanson JM, Fishel DG</AU>
<TI>Estrogen replacement therapy and postural stability in the elderly</TI>
<SO>American Journal of Otology</SO>
<YR>1995</YR>
<VL>16</VL>
<PG>470-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-2005" NAME="Greenspan 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan SL, Resnick NM, Parker RA</AU>
<TI>The effect of hormone replacement on physical performance in community-dwelling elderly women</TI>
<SO>American Journal of Medicine</SO>
<YR>2005</YR>
<VL>118</VL>
<PG>1232-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hackman-1977" NAME="Hackman 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hackman BW, Galbraith D</AU>
<TI>Six month study of oestrogen therapy with piperazine oestrone sulphate ('Harmogen') and its effects on memory</TI>
<SO>Current Medical Research Opinion</SO>
<YR>1977</YR>
<VL>4</VL>
<NO>3</NO>
<PG>21-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janowsky-2000" NAME="Janowsky 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janowsky JS, Chavez B</AU>
<TI>Sex steroids modify working memory</TI>
<SO>Journal of Cognitive Neuroscience</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>407-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linzmayer-2001" NAME="Linzmayer 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linzmayer L, Semlitsch HV, Saletu B, Saletu-Zyhlarz G, Zoghlami A, Gruber D, et al</AU>
<TI>Double-blind, placebo-controlled psychometric studies of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients</TI>
<SO>Arzneimittel Forschung/Drug Research</SO>
<YR>2001</YR>
<VL>51</VL>
<NO>I</NO>
<PG>238-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phillips-1992" NAME="Phillips 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillips SM, Sherwin BB</AU>
<TI>Effects of estrogen on memory function in surgically menopausal women</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>1992</YR>
<VL>17</VL>
<PG>485-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polo_x002d_Kantola-1998" NAME="Polo-Kantola 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polo-Kantola P, Portin R, Polo O, Helenius H, Irjala K, Erkkola R</AU>
<TI>The effect of short- term estrogen replacement therapy on cognition: a randomized double-blind, cross-over trial in postmenopausal women</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1998</YR>
<VL>91</VL>
<NO>3, March</NO>
<PG>459-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Resnick-2006" NAME="Resnick 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resnic SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, et al. for the Women's Health Initiative Study of Cognitive Aging Investigators</AU>
<TI>Effects of combination estrogen plus progestin hormone treatment on cognition and affect</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>5</NO>
<PG>1802-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaywitz-1999" NAME="Shaywitz 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaywitz SE, Shaywitz BE, Pugh KR, Fulbright RK, Skudlarski P, Mencl WE, et al</AU>
<TI>Effects of estrogen on brain activation patterns in postmenopausal women during working memory tasks</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>13</NO>
<PG>1197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherwin-1988" NAME="Sherwin 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherwin BB</AU>
<TI>Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>1988</YR>
<VL>13</VL>
<PG>345-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sherwin-1990" NAME="Sherwin 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sherwin BB, Phillips S</AU>
<TI>Estrogen and cognitive functioning in surgically menopausal women</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1990</YR>
<VL>592</VL>
<PG>474-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shumaker-2003" NAME="Shumaker 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al. for the WHIMS Investigators</AU>
<TI>Effect of estrogen plus progestin on global cognitive function in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<PG>2663-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shumaker SA, Legault C, Thal L, Wallace RB, Ockene JK, Hendrix SL, et al</AU>
<TI>Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>20</NO>
<PG>2651-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shumaker-2004" NAME="Shumaker 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al. for the WHIMS Investigators</AU>
<TI>Conjugated equine estrogens and global cognitive function in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>24</NO>
<PG>2959-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Women's Health Initiative Memory Study</AU>
<TI>Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>24</NO>
<PG>2947-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanhulle-1976" NAME="Vanhulle 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="BOOK">
<AU>Vanhulle G, Demol R</AU>
<TI>A double-blind study into the influences of estriol on a number of psychological tests in postmenopausal women</TI>
<SO>Consensus on Menopausal Research</SO>
<YR>1976</YR>
<PG>94-9</PG>
<ED>van Keep PA, Greenblatt RB, Albeaux-Fernet M</ED>
<PB>MTP Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolf-1999" NAME="Wolf 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolf OT, Kudielka BM, Hellhammer DH, Toerber S, McEwen BS, Kirschbaum C</AU>
<TI>Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>1999</YR>
<VL>24</VL>
<PG>727-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yaffe-2006" NAME="Yaffe 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yaffe K, Vittinghoff E, Ensrud KE, Johnson KC, Diem S, Hanes V, et al</AU>
<TI>Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life</TI>
<SO>Archives of Neurology</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>945-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Drapier-2005" NAME="Drapier 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drapier Faure E, Azoulay C, Abramovici Y</AU>
<TI>Acceptabilite par les patientes d'un THS combine continu versus cyclique: une etude clinique randomisee multicentrique francaise. [Acceptability of continuous combined versus cyclical HRT: a French multicentric randomized clinical study]</TI>
<SO>Gynecologie, obstetrique and fertilite</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>7-8</NO>
<PG>498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friebely-2001" NAME="Friebely 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friebely JS, Shifren JL, Schiff I, Regestein QR</AU>
<TI>Preliminary observations on differing psychological effects of conjugated and esterified estrogen treatments</TI>
<SO>Journal of Womens Health and Gender Based Medicine</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>2</NO>
<PG>181-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grady-2002" NAME="Grady 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E</AU>
<TI>Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study</TI>
<SO>American Journal of Medicine</SO>
<YR>2002</YR>
<VL>113</VL>
<PG>543-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greendale-1997" NAME="Greendale 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greendale GA, Melton B, Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators</AU>
<TI>Effects of estrogen or estrogen/progestins on physical, cognitive, and affective symptoms</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>S25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogervorst-1999" NAME="Hogervorst 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogervorst E, Boshuisen M, Riedel WJ, Willekes C, Jolles J</AU>
<TI>The effect of hormone replacement therapy on cognitive function in elderly women</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>1999</YR>
<VL>24</VL>
<PG>43-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krug-2003" NAME="Krug 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krug R, Molle M, Dodt C, Fehm HL, Born J</AU>
<TI>Acute influences of estrogen and testosterone on divergent and convergent thinking in postmenopausal women</TI>
<SO>Neuropsychopharmacology official publication of the American College of Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1538-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maki-2004" NAME="Maki 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maki PM, Resnick SM, Brandt J, Dobs AR, Durso SC, McCrae RR, University of Illinois at Chicago, Chicago</AU>
<TI>Changes in self-reported personality coincident with declines in cognition: results from parallel hormone therapy trials in elderly men and women</TI>
<SO>NeuroBiology of Aging</SO>
<YR>2004</YR>
<VL>25</VL>
<NO>S2</NO>
<PG>106</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McDonald-1952" NAME="McDonald 1952" YEAR="1952">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McDonald Caldwell B, Watson RI</AU>
<TI>An evaluation of psychologic effects of sex hormone administration in aged women</TI>
<SO>Journal of Gerontology</SO>
<YR>1952</YR>
<VL>7</VL>
<NO>2</NO>
<PG>228-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Michael-1970" NAME="Michael 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;197012&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Michael CM, Kantor HI, Shore H</AU>
<TI>Further psychometric evaluation of older women-the effect of estrogen administration</TI>
<SO>Journal of Gerontology</SO>
<YR>1970</YR>
<VL>25</VL>
<NO>4</NO>
<PG>337-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Natale-2001" NAME="Natale 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Natale V, Albertazzi P, Zini M, Di Micco R</AU>
<TI>Exploration of cyclical changes in memory and mood in postmenopausal women taking sequential combined oestrogen and progestogen preparations</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>2001</YR>
<VL>108</VL>
<PG>286-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen-2006" NAME="Nielsen 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nielsen TF, Ravn P, Pitkin J, Christiansen C</AU>
<TI>Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study</TI>
<SO>Maturitas</SO>
<YR>2006</YR>
<VL>53</VL>
<NO>2</NO>
<PG>184-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohkura-1998" NAME="Ohkura 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ohkura T</AU>
<TI>Sex steroids and brain function</TI>
<SO>Acta Obstetrica et Gynaecologica Japonica</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>8</NO>
<PG>633-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2003" NAME="Pan 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan HA, Wang ST, Pai MC, Chen CH, Wu MH, Huang KE</AU>
<TI>Cognitive function variations in postmenopausal women treated with continuous, combined hrt or tibolone: a comparison</TI>
<SO>Journal of Reproductive Medicine for the Obstetrician and Gynecologist</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>5</NO>
<PG>375-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauker-1958" NAME="Pauker 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pauker JD, Kheim T, Mensh I, Kountz WB</AU>
<TI>Sex hormone replacement in the aged: Psychological and medical evaluation of administration of androgen-estrogen and of androgen-estrogen combined with reserpine</TI>
<SO>Journal of Gerontology</SO>
<YR>1958</YR>
<VL>12</VL>
<PG>389-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Rasgon-2005" NAME="Rasgon 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Rasgon N</AU>
<TI>Estrogen use in protection from cognitive decline</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2005a</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rauramo-1975" NAME="Rauramo 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rauramo L, Lagerspetz K, Engblom P, Punnonen R</AU>
<TI>The effect of castration and peroral estrogen therapy on some psychological functions</TI>
<SO>Frontiers of Hormone Research</SO>
<YR>1975</YR>
<VL>3</VL>
<PG>94-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryan-2001" NAME="Ryan 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Update : 20010823&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryan N, Rosner A</AU>
<TI>Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women</TI>
<SO>Clinical Therapeutics</SO>
<YR>2001</YR>
<VL>23</VL>
<NO>7</NO>
<PG>1099-115</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevens-2005" NAME="Stevens 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevens MC, Clark VP, Prestwood KM</AU>
<TI>Low-dose estradiol alters brain activity</TI>
<SO>Psychiatry Research</SO>
<YR>2005</YR>
<VL>139</VL>
<NO>3</NO>
<PG>199-217</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tierney-2005" NAME="Tierney 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Tierney MC</AU>
<TI>Estrogen trial to delay the onset of Alzheimer's disease</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>(accessed 2005)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viscoli-2005" NAME="Viscoli 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI</AU>
<TI>Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST)</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<PG>387-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wisniewski-2002" NAME="Wisniewski 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wisniewski AB, Nguyen TT, Dobs AS</AU>
<TI>Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone treatment on cognitive task performance in postmenopausal women</TI>
<SO>Hormone Research</SO>
<YR>2002</YR>
<VL>58</VL>
<NO>3</NO>
<PG>150-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Dumas-2006" NAME="Dumas 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P</AU>
<TI>Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>2065-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joffe-2006" NAME="Joffe 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joffe H, Hall JE, Gruber S, Sarmiento IA, Cohen LS, Yurgelun-Todd D, Martin KA</AU>
<TI>Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized double-blind placebo-controlled study with functional magnetci resonance imaging in perimenopausal and recently postmenopausal women</TI>
<SO>Menopause</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>3</NO>
<PG>411-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LeBlanc-2007" NAME="LeBlanc 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LeBlanc ES, Neiss MB, Carello PE, Samuels MH, Janowsky JS</AU>
<TI>Hot flashes and estrogen therapy do not influence cognition in early menopausal women</TI>
<SO>Menopause</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>2</NO>
<PG>191-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiff-2005" NAME="Schiff 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiff R, Bulpitt CJ, Wesnes KA, Rajkumar C</AU>
<TI>Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>4</NO>
<PG>309-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kronos-2006" NAME="Kronos 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Crenshaw P</AU>
<TI>Kronos Early Estrogen Prevention Study (KEEPS)</TI>
<SO>Metaregister of Current Controlled Clinical Trials</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raghnauth-2000" NAME="Raghnauth 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Raghnauth A</AU>
<TI>Dementia prevention study for healthy women</TI>
<SO>Centerwatch</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-06-05 14:11:28 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Barrett_x002d_Connor-1991" NAME="Barrett-Connor 1991" TYPE="JOURNAL_ARTICLE">
<AU>Barrett-Connor E</AU>
<TI>Postmenopausal estrogen and prevention bias</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>115</VL>
<PG>455-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-2001" NAME="Bland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bland RC, Newman SC</AU>
<TI>Mild dementia or cognitive impairment: the Modified Mini-Mental State examination (3MS) as a screen for dementia</TI>
<SO>Canadian Journal of Psychiatry</SO>
<YR>2001</YR>
<VL>46</VL>
<PG>506-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farquhar-2005" NAME="Farquhar 2005" TYPE="COCHRANE_REVIEW">
<AU>Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA and the Cochrane Hormone Therapy Study Group</AU>
<TI>Long term hormone therapy for perimenopausal and postmenopausal women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fratiglioni-2000" NAME="Fratiglioni 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al</AU>
<TI>Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>11</NO>
<PG>S10-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-2004" NAME="Henderson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Henderson VW</AU>
<TI>Hormone therapy and Alzheimer's disease: benefit or harm?</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>2</NO>
<PG>389-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogervorst-2000" NAME="Hogervorst 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hogervorst E, Williams J, Budge M, Riedel W, Jolles J</AU>
<TI>The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis</TI>
<SO>Neuroscience</SO>
<YR>2000</YR>
<VL>101</VL>
<NO>3</NO>
<PG>485-512</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogervorst-2002-b" NAME="Hogervorst 2002 b" TYPE="COCHRANE_REVIEW">
<AU>Hogervorst E, Yaffe K, Richards M, Huppert F</AU>
<TI>Hormone replacement therapy to maintain cognitive function in women with dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huppert-1997" NAME="Huppert 1997" TYPE="JOURNAL_ARTICLE">
<AU>Huppert F, Wilcock G</AU>
<TI>Ageing, cognition and dementia</TI>
<SO>Age and Ageing</SO>
<YR>1997</YR>
<VL>Dec 26</VL>
<NO>Suppl 4</NO>
<PG>20-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Launer-1999" NAME="Launer 1999" TYPE="JOURNAL_ARTICLE">
<AU>Launer LJ, Andersen K, Dewy ME, Letenneur L, Ott A, Amaducci LA, et al</AU>
<TI>Rates and risk factors for dementia and Alzheimer's disease</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>1</VL>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LeBlanc-2001" NAME="LeBlanc 2001" TYPE="JOURNAL_ARTICLE">
<AU>LeBlanc ES, Janowsky J, Chan BKS, Nelson HD</AU>
<TI>Hormone replacement therapy and cognition</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>11</NO>
<PG>1489-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maki-2005" NAME="Maki 2005" TYPE="JOURNAL_ARTICLE">
<AU>Maki PM</AU>
<TI>A systematic review of clinical trials of hormone therapy on cognitive function</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2005</YR>
<VL>1052</VL>
<PG>182-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maki-2006" NAME="Maki 2006" TYPE="JOURNAL_ARTICLE">
<AU>Maki PM</AU>
<TI>Hormone therapy and cognitive function: is there a critical period for benefit?</TI>
<SO>Neuroscience</SO>
<YR>2006</YR>
<VL>138</VL>
<PG>1027-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matthews-1996" NAME="Matthews 1996" TYPE="JOURNAL_ARTICLE">
<AU>Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P</AU>
<TI>Prior to use of estrogen replacement therapy: are users healthier than nonusers?</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1996</YR>
<VL>143</VL>
<NO>10</NO>
<PG>971-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McEwen-1997" NAME="McEwen 1997" TYPE="JOURNAL_ARTICLE">
<AU>McEwen BS, Alves SE, Bulloch K, Weiland NG</AU>
<TI>Ovarian steroids and the brain implications for cognition and aging</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<PG>S14-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nappi-1999" NAME="Nappi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nappi RE, Sinforiani E, Mauri M, Bono G, Polatti F, Nappi G</AU>
<TI>Memory functioning at menopause: impact of age in ovariectomized women</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>1999</YR>
<VL>47</VL>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sherwin-2003" NAME="Sherwin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sherwin BB</AU>
<TI>Estrogen and cognitive functioning in women</TI>
<SO>Endocrine Reviews</SO>
<YR>2003</YR>
<VL>24</VL>
<PG>133-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silva-2001" NAME="Silva 2001" TYPE="JOURNAL_ARTICLE">
<AU>Silva I, Mor G, Naftolin F</AU>
<TI>Estrogen and the aging brain</TI>
<SO>Maturitas</SO>
<YR>2001</YR>
<VL>Feb 28;38</VL>
<NO>1</NO>
<PG>100-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yaffe-1998-a" NAME="Yaffe 1998 a" TYPE="JOURNAL_ARTICLE">
<AU>Yaffe K, Sawaya G, Lieberburg I, Grady D</AU>
<TI>Estrogen therapy in postmenopausal women</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>279</VL>
<PG>688-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yaffe-1998-b" NAME="Yaffe 1998 b" TYPE="JOURNAL_ARTICLE">
<AU>Yaffe K, Grady D, Pressman A, Cummings S</AU>
<TI>Serum estrogen levels, cognitive performance and risk of cognitive decline in older community women</TI>
<SO>JAGS</SO>
<YR>1998</YR>
<VL>46</VL>
<PG>816-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yaffe-2000" NAME="Yaffe 2000" TYPE="JOURNAL_ARTICLE">
<AU>Yaffe K, Lui L-Y, Grady D, Cauley J, Kramer J, Cummings SR</AU>
<TI>Cognitive decline in women with relation to non-protein bound estradiol concentrations</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9231</NO>
<PG>708-12</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-06-05 14:11:28 +0100" MODIFIED_BY="Helen Collins">
<REFERENCE ID="REF-Hogervorst-2002a" MODIFIED="2008-06-05 14:11:28 +0100" MODIFIED_BY="Helen Collins" NAME="Hogervorst 2002a" TYPE="COCHRANE_REVIEW">
<AU>Hogervorst E, Yaffe K, Richards M, Huppert F</AU>
<TI>Hormone replacement therapy for cognitive function in postmenopausal women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-06-05 14:11:28 +0100" MODIFIED_BY="Helen Collins"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Almeida-2006">
<CHAR_METHODS>
<P>Design: randomized, double-blind, parallel groups, 20 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia, n = 86 healthy women over 70, mean age = 73.8, natural or surgical menopause not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 oral (0.5 mg weeks 1 to 2; 1 mg weeks 3 to 4; 2 mg weeks 5 to 16; 1 mg weeks 17 to 18; 0.5 mg weeks 19 to 20)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-General: CAMCOG<BR/>-Verbal memory/language: CVLT (IR+DR), Verbal Fluency, Faces (IR+DR)<BR/>-Visuospatial: Block Design</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT &gt; placebo 1/5 tests (Faces - immediate recall, not delayed recall). No effect: CAMCOG, Verbal Fluency, CVLT, Block Design</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Binder-2001">
<CHAR_METHODS>
<P>Design: randomized double-blind parallel<BR/>groups<BR/>9 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>n = 52 elderly healthy women, mean age 82 (75 to 91 years), mixed natural and surgical menopause ? Exclusion criteria: dementia, depression, HRT contraindications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral 0.625 mg/day + (in women without hysterectomy) MPA 5 mg for 13 days every third month<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Verbal Memory: Paired Associate Learning, Verbal Fluency<BR/>- Speed/concentration: Trial Making Test (TMT) A / B, Cancellation Random Letters and Figures test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect HRT<BR/>0/5 tests</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ditkoff-1991">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind<BR/>parallel groups <BR/>3 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA <BR/>n = 36 healthy women, mean age: 53 (45 to 60) Hysterectomized, asymptomatic patients<BR/>Exclusion criteria: active disease or psychoactive medication use</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral 0.625 or 1.25 mg/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Short term memory (STM) and Concentration (Digit Span)<BR/>- Speed (Digit Symbol Modalities test or DSST)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect HRT<BR/>0/2 tests</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Duka-2000">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind<BR/>parallel groups<BR/>3 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK <BR/>n = 37 healthy women, mean age: 65 (55 to 75). Natural menopausal ? Status unclear.<BR/>Exclusion criteria: abnormal weight, mental, neurological, or chronic disease, substance abuse<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 17 beta E2 transdermal patch (0.1 mg /day)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Visual Memory: Picture Recall (BETAM), Visual Paired Associates Learning (CANTAB) <BR/>- Visuospatial speed: mental rotation/ reaction time (RT) <BR/>- Executive function: CANTAB ID/ED test, Stroop , Random Number Generation Test, Tower of London</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT&gt; placebo memory (BETAM and PAL) and visual rotation speed, 3/ 7 tests (baseline differences seem larger than effect size)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dunkin-2005">
<CHAR_METHODS>
<P>Design: randomized, double-blind, parallel groups, 10 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA n = 17, healthy women, mean age 57, natural or surgical menopause not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 transdermal 0.1 mg/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Verbal memory/language : CVLT, WMS-R PAL and logical memory, Fluency<BR/>-Non-verbal memory: WMS-R VRT, Rey-Osterreith<BR/>-Attention, Speed processing, Executive functions: Stroop, Grooved Pegboard Test WCST, TMT-B, Digit Span, DSST, WAIS-R picture arrangement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect of HRT 0/13 tests (but trend level significance in attention and speed of information processing tests combined)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fedor_x002d_Freyberg-1977">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups <BR/>3 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Sweden <BR/>n = 21 women with many climacteric symptoms, mean age: 57 (47 to 70). <BR/>Exclusion criteria: mental disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 oral 2 mg/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Speed/concentration: Choice RT, KVT (visual search) , Stroop, USTM test (attention, STM &amp; reasoning), Visual Search test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT &gt; placebo 5/5 tests</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Goebel-1995">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups <BR/>2, 4 and 8<BR/>months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>n = 87 elderly women, mean age: 75 (70 to 88) Exclusion criteria: age &lt; 69, smoking, psychotrophic medication, depression, cancer, liver or vascular disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral 0.625 mg (+ MPA 5 mg for 12 days every third month)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Speed: TMT-B</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect HRT <BR/>0/1 test</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Greenspan-2005">
<CHAR_METHODS>
<P>Design:<BR/>randomized double-blind parallel groups, 3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA, n = 373 healthy women, mean age 71.3 years, 243 with a uterus and 130 without a uterus</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral (0.625 mg/day) or CEE oral (0.625 mg/day) + medroxyprogesterone acetate (2.5 mg/day)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- General: MMSE</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect of HRT 0/1 test<BR/>Half of the participants also took alendronate and all participants had co-intervention (calcium and vitamin D supplement and a multivitamin)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hackman-1977">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups, <BR/>6 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: UK<BR/>n = 18 healthy women, aged between 29 and 68 years. Mixed surgical and natural menopausal, many climacteric symptoms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. piperazine E1 oral , 1.5 mg/2x day<BR/>2. Placebo 2x day for 3 weeks each month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Verbal memory: Guild memory test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect HRT<BR/>0/1 test</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Janowsky-2000">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups <BR/>1 month<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>n = 13 healthy women, mean age: 69 (61 to 74) Natural menopausal ? (all had normal gynaecological exams)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE 0.625 mg/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Visual memory: Working memory task (with abstract figures)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect HRT <BR/>0/1 test</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Linzmayer-2001">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups (3-arm trial) <BR/>2 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Austria<BR/>n = 49, mean age: 58 (46 to 67 years). Mixed ? natural and surgical. Inclusion: Sleep disorder (DSM), menopausal &gt; 24 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 valerate (2 mg) + dienogest (P, 3 mg)/day<BR/>2. E2 2 mg/day<BR/>3. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Verbal memory (Grunberger, also includes associative, numeric and total verbal meory)<BR/>- Visual memory (Benton Visual Retention Test)<BR/>- Intelligence (Mehrfachwahl-Wortschatz Test or MWT)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT E2+P&gt; E2/ Placebo on associative verbal memory <BR/>E2 &gt; E2+P on numerical memory (baseline difference)<BR/>E2+P &gt;E2 on visual memory (only after open label, 4 mnth HRT)<BR/>No effect Intelligence or other verbal memory</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Phillips-1992">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups<BR/>2 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada<BR/>n = 19 healthy women, mean age: 48 (SD 5) <BR/>All surgical menopausal. Exclusion criteria: contra-indications for HRT, mental disease, ever use HRT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 (I.M.) 10 mg/month<BR/>2. Placebo (I.M. sesame oil 1 ml)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Verbal memory: Paragraph recall, Paired Associate learning, Digit Span<BR/>- Visuospatial Memory: Visual Reproduction Test (VRT of the Wechsler Memory Scale or WMS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT &gt; placebo <BR/>2/4 tests: verbal memory (not digit span) no effect VRT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Polo_x002d_Kantola-1998">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind cross-over, <BR/>3 months drug-1 month- 3 month drug wash-out</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland<BR/>n=62 very healthy hysterectomized women, mean age: 56 (47 to 65). Exclusion criteria: neurological, cardiovascular, endocrinological, and mental disease, malignancies, smoking &gt;10 cigarettes, psychoactive medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 transdermal 2.5 mg/day (&lt; 56 years of age) or 0.05 mg/day (&gt; 55 years of age)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Memory: Benton Visual Retention Test (BVRT) and Digit Span<BR/>- Speed: Stroop, RT, Letter cancellation, Paced Auditory Serial Addition Test (PASAT), DSST, substraction test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>no effect HRT <BR/>0/8 tests</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Resnick-2006">
<CHAR_METHODS>
<P>Design: randomised, double-blind, parallel groups, 3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA n = 1417 (subgroup WHIMS), mean age 73.7, healthy women, natural or surgical menopause not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral (0.625 mg/day) + medroxyprogesterone (2.5 mg/day)<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-General/Verbal knowledge: PMA vocabulary<BR/>-Memory/language: BVRT, CVLT (IR+DR), Verbal Fluency (2 types)<BR/>-Attention, working memory: Digit Span forward and backwards<BR/>-Spatial ability: Card Rotations<BR/>-Fine motor skills: Finger tapping</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT &gt;placebo 1/9 tests (BVRT) <BR/>Placebo&gt;HRT 1/9 tests (CVLT)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shaywitz-1999">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind cross-over, 21 days drug-14 days wash-out- 21 days drug<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>n = 46 healthy postmenopausal, mean age: 51 (SD 5, 33 to 61). Exclusion criteria: MRI abnormalities, IQ&lt; 85, &lt;5 months postmenopausal, HRT for last 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral 1.25 mg/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Memory: word and token recall</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect HRT <BR/>0/2 tests</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sherwin-1988">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind cross-over<BR/>3 months drug-1 month placebo- 3 month drug</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada<BR/>n = 50, healthy women, mean age: 45.4. All surgically menopausal. Exclusion criteria: psychological problems.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 (I.M. 10 mg/ mnth), n=10<BR/>2. E2 (I.M. 8.5 mg)+ T (I.M. 150 mg) /mnth, n=10<BR/>3. T (I.M. 200 mg/mnth), n=10<BR/>4. Placebo, n=10</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Memory: Digit Span, Paragraph recall (not WMS!) <BR/>- Speed: Clerical speed and accuracy<BR/>- Abstract reasoning</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ERT &gt; placebo <BR/>4/4 tests<BR/>TRT=ERT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sherwin-1990">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups,<BR/>2 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Canada<BR/>n=12 healthy women, mean age: 47. All surgical menopausal. Exclusion criteria: psychological or physical disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 (I.M.) 10 mg/month<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Verbal memory: Paragraph recall, Paired Associate Learning, Digit span (not sure, mentions 4 tests), <BR/>- Visuospatial memory: VRT (WMS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT &gt; placebo<BR/>2/4 tests, not on VRT</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shumaker-2003">
<CHAR_METHODS>
<P>Design: randomised, double-blind, parallel groups, 7 years (mean 4.2 years)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA n = 4344, healthy women (WHIMS participants) age: 65 + (half below 70 years of age)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral 0.625 mg/day<BR/>+ 2.5 mg MPA<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- General: 3 MSE<BR/>- Diagnosis of mild cognitive impairment (defined by a standardised protocol)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Placebo&gt;HRT 1/1 test. More women in HT group had substantial decline</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shumaker-2004">
<CHAR_METHODS>
<P>Design: randomised, double-blind, parallel groups, 7 years (mean 5.4 years)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA n = 2808, healthy women (WHIMS participants), mean age: 72 (65 to 79 years), hysterectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. CEE oral 0.625 mg/day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- General:3MSE<BR/>- Diagnosis of mild cognitive impairment defined by a standardised protocol</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Placebo&gt;HRT 1/1 test</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Vanhulle-1976">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind parallel groups,<BR/>3 months<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Belgium<BR/>n = 26 healthy postmenopausal nuns, mean age: 57.6. Mixed surgical and natural menopausal Exclusion criteria: HRT or tranquillizer use</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E3 oral <BR/>4 mg/daily<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Memory: BVRT, Digit span, Labyrint of Rey <BR/>- Speed/concentration: DSST, calculations, vigilance test, Bourdon- Wiersma (B-W) test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>HRT&gt; placebo 2/7 tests of alertness and attention (vigilance and B-W test), not on memory and concentration<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wolf-1999">
<CHAR_METHODS>
<P>Design: <BR/>randomized <BR/>double-blind<BR/>parallel groups, 2 weeks<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>n = 38, healthy women, mean age: 69 (SD 6). <BR/>Mixed surgical and natural menopausal. <BR/>Exclusion criteria: psychiatric, endocrine, cardiovascular or other chronic disease, use of psychoactive medication and steroids.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. E2 transdermal, 0.1 mg/ day<BR/>2. Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>- Verbal memory: Paired Word recall, Verbal Fluency <BR/>- Visuospatial memory: Route finding <BR/>- Mental rotation test (different from Duka)<BR/>- Speed/concentration: Stroop test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect HRT <BR/>0/3 test</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Yaffe-2006">
<CHAR_METHODS>
<P>Design:<BR/>randomized triple-blind parallel groups<BR/>2 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>n = 417 women, mean age 67 years (range 60 to 80 years), intact uterus, at least 5 years beyond menopause, normal bone density for age<BR/>Exclusion: unexplained bleeding, endometrial hyperplasia or endometrium &gt;5mm, abnormal mammogram, history of metabolic bone disease, cancer, coronary disease stroke or TIA, venous thromboembolism, uncontrolled hypertension, uncontrolled thyroid disease, live disease, fasting triglyceride level &gt;180mg/dL, ever taken fluoride calcitonin or bisphosphonates, or taken E or P within 3 months of randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. 3.25 cm2 estradiol patch (approx 0.014 mg estradiol/day)<BR/>2. Placebo patch<BR/>All participants had concomitant oral supplements of 400mg calcium (twice daily) and 400IU of vitamin D once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>All secondary outcomes:<BR/>- General: 3MSE<BR/>- Episodic memory: Logical Memory, Immediate and Delayed, Brief Visuospatial Memory Test Immediate and Delayed, Word List Memory, Word List Recall<BR/>- Attention, visual scanning and executive function: Trails B Test<BR/>- Language function: Modified Boston Naming Test<BR/>- Semantic memory and language: Verbal Fluency Test</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No effect</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Drapier-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>This RCT was a dose finding study with two HRT groups and no placebo control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Friebely-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>This RCT was a dose finding study with two HRT groups and no placebo control.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grady-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants had cardiovascular disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Greendale-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Measurement of cognitive outcomes was not by validated scales but were self-reports of the participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hogervorst-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krug-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This RCT compared the effects of estrogen and testosterone; there was no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maki-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Primary outcomes were measures of self-reported personality changes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McDonald-1952">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded (androgens and progesterone also given).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Michael-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>No measure of cognition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Natale-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nielsen-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes were measured by the Women's Health Questionnaire, self reports by the participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ohkura-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This RCT compared HRT with tibolone; there was no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pauker-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Confounded; no objective measure of cognition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rasgon-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single blind trial. The inclusion criteria for the review specify that included studies must be double blind.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rauramo-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ryan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No measure of cognition.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stevens-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome was the measurement of hemodynamic activity using MRI; this is a surrogate outcome.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tierney-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants were 'memory impaired'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Viscoli-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants had cerebrovascular disease.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wisniewski-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>A comparison of estrogen with estrogen plus testosterone: there was no control group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Dumas-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Joffe-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-LeBlanc-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Schiff-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Kronos-2006">
<CHAR_STUDY_NAME>
<P>Kronos Early Estrogen Prevention Study (KEEPS)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Healthy women within 3 years of the menopause</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(1) CEE 0.45mg/day<BR/>(2) Transdermal estradiol 50 MCG/day<BR/>(3) Micronized progesterone 200mg/day X 12d/mth<BR/>(4) Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary:<BR/>Rate of change of carotid intimal medial thickness by ultrasound<BR/>Secondary:<BR/>(1) Plasma lipid profiles<BR/>(2) Blood clotting factors<BR/>(3) Serum inflammatory markers<BR/>(4) Hromone levels<BR/>(5) Cognitive and affective scores on standard psychometric tests<BR/>(6) Quality of life</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>September 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Patricia Crenshaw (info@kronosinstitute.org</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Multicenter trial with expected completion in December 2010.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Raghnauth-2000">
<CHAR_STUDY_NAME>
<P>Alzheimer's disease prevention trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Healthy women &gt;65 years who have a family history of memory problems and Alzheimer's disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>(1) Estrogen - unknown dose<BR/>(2) Estrogen + progestogen - unknown dose<BR/>(3) Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Prevention of dementia</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>unknown</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>A. Raghnauth, Columbia-Presbyterian Medical Center, G.H. Sergiesvsky Center.<BR/>sdm9001@nyp.org</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sponsored by the National Institute on Aging (NIA) in the USA</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-06-05 14:09:05 +0100" MODIFIED_BY="Helen Collins" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-06-05 13:54:47 +0100" MODIFIED_BY="Helen Collins">
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Quality of included studies</TITLE>
<TABLE COLS="7" ROWS="17">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Randomisation method</P>
</TH>
<TH>
<P>All concealment</P>
</TH>
<TH>
<P>Attrition</P>
</TH>
<TH>
<P>Power calculation</P>
</TH>
<TH>
<P>Intention to treat</P>
</TH>
<TH>
<P>Prognostic balance</P>
</TH>
</TR>
<TR>
<TD>
<P>Almeida 2006</P>
</TD>
<TD>
<P>Random list of numbers generated by computer - randomisation in blocks of 8</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>17.5% in ERT group and 32.8% in placebo group dropped out either because of side effects, withdrawal of consent or health problems</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Yes - also completers analysis performed</P>
</TD>
<TD>
<P>Balanced for age, education, cognitive test scores, prior use of HRT, quality of life, depression and history of psychiatric treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Binder 2001</P>
</TD>
<TD>
<P>Computer generated random permutation procedure in 2:1 ratio</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>22% (10/45) in ERT/HRT group and 4.5% of women in the placebo group dropped out. A further 4 women were excluded (2% in HRT group; 14% in placebo group) because of depression or mild cognitive impairment</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Balanced for age, education, ethnic origin, medications, smoking status, comorbidities and previous HRT use</P>
</TD>
</TR>
<TR>
<TD>
<P>Duka 2000</P>
</TD>
<TD>
<P>Supplied by the pharmaceutical company that supplied the treatment - no details given</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Nil</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Balanced for age and education</P>
</TD>
</TR>
<TR>
<TD>
<P>Dunkin 2005</P>
</TD>
<TD>
<P>Not described</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>33% of ERT group and 36% of placebo group dropped out because of time constraints, concern over randomisation or being lost to follow up</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Balanced for age, IQ, education, ratio of surgical or natural menopause, prior use of ERT, BMI and parity</P>
</TD>
</TR>
<TR>
<TD>
<P>Greenspan 2005</P>
</TD>
<TD>
<P>Randomized lists prepared by the study statistician</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>9.6% of HRT/ERT group and 9.7% of placebo group with similar reasons for each group</P>
</TD>
<TD>
<P>Yes, 80% power to detect a difference &gt;2.91 times the within group SD</P>
</TD>
<TD>
<P>Yes, also per protocol analysis</P>
</TD>
<TD>
<P>Balanced for age, BMI, physical performance, functional assessment and MMSE scores</P>
</TD>
</TR>
<TR>
<TD>
<P>Hackman 1977</P>
</TD>
<TD>
<P>"Coding system"</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>10% (1/10) of ERT group and 10% (1/10) of control group dropped out before the end of the trial and were not included in the analyses</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Janowsky 2000</P>
</TD>
<TD>
<P>Not described</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Balanced for age and education</P>
</TD>
</TR>
<TR>
<TD>
<P>Linzmayer 2001</P>
</TD>
<TD>
<P>Not described</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Phillips 1992</P>
</TD>
<TD>
<P>Not described</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>19% (6/31) of study group dropped out initially and another 19% (6/31) dropped out as a result of severe menopausal symptoms after surgery</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Balanced for age, education, memory, mood and menopausal symptoms</P>
</TD>
</TR>
<TR>
<TD>
<P>Resnick 2006</P>
</TD>
<TD>
<P>Permutated block algorithm according to age group and clinical centre site</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>At the conclusion of the trial (mean follow up 1.35 years), 6.7% of HRT group and 6.9% of placebo group had either died or had dropped out</P>
</TD>
<TD>
<P>Yes, 90% power to detect an observed 50% treatment associated slowing of declines in cognition and memory</P>
</TD>
<TD>
<P>No, data not carried forward for dropouts</P>
</TD>
<TD>
<P>Balanced for age, 3MSE scores, education, ethnicity, BMI, smoking status, prior CVD, hypertension, alcohol use, diabetes, vasomotor symptoms and prior HRT use</P>
</TD>
</TR>
<TR>
<TD>
<P>Sherwin 1988</P>
</TD>
<TD>
<P>Not described</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>17% (9/53) of original study group (another 6 women were recruited and randomised)</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Balanced for age, education, occupation, personality and marital adjustment</P>
</TD>
</TR>
<TR>
<TD>
<P>Sherwin 1990</P>
</TD>
<TD>
<P>Not described</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD>
<P>Shumaker 2003</P>
</TD>
<TD>
<P>Permutated block algorithm stratified according to age group and clinical centre site</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>2.5% of HRT group and 1.9% of placebo group either refused further testing, had incomplete data or died</P>
</TD>
<TD>
<P>Yes, 80% power to detect a 40% reduction in the incidence of dementia</P>
</TD>
<TD>
<P>Yes, for mild cognitive improvement outcome</P>
</TD>
<TD>
<P>Balanced for age, education, smoking status, history of stroke or diabetes, prior hormone use and 3MSE scores</P>
</TD>
</TR>
<TR>
<TD>
<P>Shumaker 2004</P>
</TD>
<TD>
<P>Permutated block algorithm stratified by age and clinical centre</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>7.2% of ERT group and 6.9% of placebo group either refused further testing, had incomplete data or died</P>
</TD>
<TD>
<P>Yes, 80% power to detect 40% reduction in dementia</P>
</TD>
<TD>
<P>Yes, for mild cognitive impairment</P>
</TD>
<TD>
<P>Balanced for age, education, ethnicity, smoking status, history of CVD or diabetes, prior hormone therapy and 3MSE scores</P>
</TD>
</TR>
<TR>
<TD>
<P>Wolf 1999</P>
</TD>
<TD>
<P>Not described</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>5% (2/40) were excluded from analysis because of non compliance</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Balanced for age, BMI and education</P>
</TD>
</TR>
<TR>
<TD>
<P>Yaffe 2006</P>
</TD>
<TD>
<P>Randomly permited blocks of 4, stratified by clinical centre</P>
</TD>
<TD>
<P>Adequate</P>
</TD>
<TD>
<P>8.2% of ERT group and 11.5% in placebo group did not complete the trial (for similar reasons)</P>
</TD>
<TD>
<P>Yes, 80% power to detect between group differences of 0.29SD of change scores</P>
</TD>
<TD>
<P>Not true ITT - dropouts not included in analysis. ITT without regard to adherence</P>
</TD>
<TD>
<P>Balanced for age, education, ethnicity, smoking status, BMI, depression, vasomotor symptoms and estradiol levels</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-06-05 13:54:47 +0100" MODIFIED_BY="Helen Collins" NO="2">
<TITLE MODIFIED="2008-06-05 13:26:31 +0100" MODIFIED_BY="Helen Collins">List of abbreviations</TITLE>
<TABLE COLS="2" ROWS="36">
<TR>
<TH VALIGN="BOTTOM">
<P>Abbreviation</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Full description</P>
</TH>
</TR>
<TR>
<TD>
<P>AD<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Alzheimer's disease</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Blessed or BIMC</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Blessed Information Memory and Concentration test</P>
</TD>
</TR>
<TR>
<TD>
<P>BSRT</P>
</TD>
<TD VALIGN="TOP">
<P>Buschke's Selective Reminding Test</P>
</TD>
</TR>
<TR>
<TD>
<P>BSO</P>
</TD>
<TD>
<P>Bilateral Salpingo-Oopherectomy (removal of the ovaries)</P>
</TD>
</TR>
<TR>
<TD>
<P>BVRT</P>
</TD>
<TD>
<P>Benton Visual Retention Test</P>
</TD>
</TR>
<TR>
<TD>
<P>CAMCOG</P>
</TD>
<TD>
<P>Cambridge Cognitive Examination for Mental Disorders of the Elderly</P>
</TD>
</TR>
<TR>
<TD>
<P>CEE</P>
</TD>
<TD>
<P>Conjugated Equine Estrogens or Premarin</P>
</TD>
</TR>
<TR>
<TD>
<P>CVLT</P>
</TD>
<TD>
<P>Californian Verbal Learning Test</P>
</TD>
</TR>
<TR>
<TD>
<P>DAT</P>
</TD>
<TD>
<P>Dementia of the Alzheimer's Type</P>
</TD>
</TR>
<TR>
<TD>
<P>Dep</P>
</TD>
<TD>
<P>depressed</P>
</TD>
</TR>
<TR>
<TD>
<P>DSM</P>
</TD>
<TD>
<P>Diagnostic Statistical Manual</P>
</TD>
</TR>
<TR>
<TD>
<P>DSST</P>
</TD>
<TD>
<P>Digit Symbol Substitution Test</P>
</TD>
</TR>
<TR>
<TD>
<P>E1</P>
</TD>
<TD>
<P>Estrone'</P>
</TD>
</TR>
<TR>
<TD>
<P>E2</P>
</TD>
<TD>
<P>Estradiol</P>
</TD>
</TR>
<TR>
<TD>
<P>E3</P>
</TD>
<TD>
<P>Estriol</P>
</TD>
</TR>
<TR>
<TD>
<P>ERT</P>
</TD>
<TD>
<P>Estrogen Replacement Therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>HRT</P>
</TD>
<TD>
<P>Hormone Replacement Therapy (estrogen plus progestagen)</P>
</TD>
</TR>
<TR>
<TD>
<P>I.M.</P>
</TD>
<TD>
<P>Intramuscular</P>
</TD>
</TR>
<TR>
<TD>
<P>MANOVA</P>
</TD>
<TD>
<P>Multivariate Analyses of Variance</P>
</TD>
</TR>
<TR>
<TD>
<P>3MSE</P>
</TD>
<TD>
<P>Mini-Mental Status Examination</P>
</TD>
</TR>
<TR>
<TD>
<P>MPA</P>
</TD>
<TD>
<P>Medroxy Progestrone Acetate</P>
</TD>
</TR>
<TR>
<TD>
<P>NINCDS/ADRDA</P>
</TD>
<TD>
<P>National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association</P>
</TD>
</TR>
<TR>
<TD>
<P>RCT</P>
</TD>
<TD>
<P>Randomized Controlled Trial</P>
</TD>
</TR>
<TR>
<TD>
<P>SD</P>
</TD>
<TD>
<P>Standard Deviation</P>
</TD>
</TR>
<TR>
<TD>
<P>SEM</P>
</TD>
<TD>
<P>Standard Error of the Mean</P>
</TD>
</TR>
<TR>
<TD>
<P>SQRT</P>
</TD>
<TD>
<P>Square Root</P>
</TD>
</TR>
<TR>
<TD>
<P>TMT</P>
</TD>
<TD>
<P>Trail Making Test</P>
</TD>
</TR>
<TR>
<TD>
<P>VaD</P>
</TD>
<TD>
<P>Vascular Dementia</P>
</TD>
</TR>
<TR>
<TD>
<P>Var</P>
</TD>
<TD>
<P>Variance</P>
</TD>
</TR>
<TR>
<TD>
<P>VRT WMS</P>
</TD>
<TD>
<P>Visual Retention Test of the WMS (Visuospatial Memory)</P>
</TD>
</TR>
<TR>
<TD>
<P>WHIMS</P>
</TD>
<TD>
<P>the Women's Health Initiative Study</P>
</TD>
</TR>
<TR>
<TD>
<P>WHISCA</P>
</TD>
<TD>
<P>the Women's Health Initiative Study of Cognitive Aging</P>
</TD>
</TR>
<TR>
<TD>
<P>WISDOM</P>
</TD>
<TD>
<P>Women's International Study of long Duration estrogen after the Menopause</P>
</TD>
</TR>
<TR>
<TD>
<P>WMD</P>
</TD>
<TD>
<P>Weighted Mean Difference</P>
</TD>
</TR>
<TR>
<TD>
<P>WMS</P>
</TD>
<TD>
<P>Wechsler Memory Scale</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>The effect of ERT/HRT versus placebo on global cognition scores</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8248844092616112" CI_START="-0.624884409261611" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.3370185122633037" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="57" UNITS="" WEIGHT="100.0" Z="0.960072952053443">
<NAME>CAMCOG after 20 weeks of E2 versus placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8248844092616112" CI_START="-0.624884409261611" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="2.6" ORDER="15012" SD_1="3.3" SD_2="3.4" SE="0.6249525087824792" STUDY_ID="STD-Almeida-2006" TOTAL_1="58" TOTAL_2="57" WEIGHT="100.0"/>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="5.1147018767246655" CI_END="-0.15673267493666354" CI_START="-0.3967103505742571" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_SIZE="-0.2767215127554603" ESTIMABLE="YES" I2="21.794073312411598" I2_Q="21.794073312411598" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.27572964105325437" P_Q="0.27572964105325437" P_Z="6.180397267219483E-6" Q="5.1147018767246655" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="5" TOTAL_2="5" WEIGHT="500.0" Z="4.52012210975161">
<NAME>3MSE score after CEE + MPA (variable follow up)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.014019699754082487" CI_START="-0.4540196997540825" DF="0.0" EFFECT_SIZE="-0.22" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-1.8532612871212468" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.06539531509588149" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.8425460636515911">
<NAME>One year follow up</NAME>
<IV_DATA CI_END="0.014019699754082487" CI_START="-0.4540196997540825" EFFECT_SIZE="-0.22" ESTIMABLE="YES" ESTIMATE="-0.22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15013" SE="0.1194" STUDY_ID="STD-Shumaker-2003" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.10931160251234062" CI_START="-0.36931160251234063" DF="0.0" EFFECT_SIZE="-0.13" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-0.9613337388768538" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Z="0.28701124400076405" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.0647010647010646">
<NAME>2 years follow up</NAME>
<IV_DATA CI_END="0.10931160251234062" CI_START="-0.36931160251234063" EFFECT_SIZE="-0.13" ESTIMABLE="YES" ESTIMATE="-0.13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15014" SE="0.1221" STUDY_ID="STD-Shumaker-2003" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.11108457396341309" CI_START="-0.6089154260365869" DF="0.0" EFFECT_SIZE="-0.36" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="1.0" P_Z="0.004587653740644495" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.8346456692913384">
<NAME>3 years follow up</NAME>
<IV_DATA CI_END="-0.11108457396341309" CI_START="-0.6089154260365869" EFFECT_SIZE="-0.36" ESTIMABLE="YES" ESTIMATE="-0.36" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15015" SE="0.127" STUDY_ID="STD-Shumaker-2003" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.230905312280342" CI_START="-0.8090946877196581" DF="0.0" EFFECT_SIZE="-0.52" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="1.0" P_Z="4.2280590853655453E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.5254237288135597">
<NAME>4 years follow up</NAME>
<IV_DATA CI_END="-0.230905312280342" CI_START="-0.8090946877196581" EFFECT_SIZE="-0.52" ESTIMABLE="YES" ESTIMATE="-0.52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15016" SE="0.1475" STUDY_ID="STD-Shumaker-2003" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.26139225667611166" CI_START="-0.5813922566761117" DF="0.0" EFFECT_SIZE="-0.16" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="-0.5827072818382817" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="5" P_CHI2="1.0" P_Z="0.456763934292984" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.7441860465116279">
<NAME>5 years follow up</NAME>
<IV_DATA CI_END="0.26139225667611166" CI_START="-0.5813922566761117" EFFECT_SIZE="-0.16" ESTIMABLE="YES" ESTIMATE="-0.16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15017" SE="0.215" STUDY_ID="STD-Shumaker-2003" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.383893183345482" CI_END="-0.15306599704484106" CI_START="-0.44207700306586484" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_SIZE="-0.29757150005535293" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="0.9355834077159435" P_Q="0.8349830575684049" P_Z="5.436186136585472E-5" Q="2.101124728320175" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="8" TOTAL_2="8" WEIGHT="600.0" Z="4.036036073253378">
<NAME>3MSE score after CEE alone (variable follow up)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.008321546017502261" CI_END="-0.1582779939123985" CI_START="-0.725933431422345" DF="1.0" EFFECT_SIZE="-0.44210571266737175" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.9273157908909792" P_Z="0.0022660518096952235" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="3.0529480277277505">
<NAME>One year follow up</NAME>
<IV_DATA CI_END="-0.11935407580809287" CI_START="-0.7806459241919071" EFFECT_SIZE="-0.45" ESTIMABLE="YES" ESTIMATE="-0.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15018" SE="0.1687" STUDY_ID="STD-Shumaker-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="73.68570889123906"/>
<IV_DATA CI_END="0.13329783283565738" CI_START="-0.9732978328356574" EFFECT_SIZE="-0.42" ESTIMABLE="YES" ESTIMATE="-0.42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15019" SE="0.2823" STUDY_ID="STD-Yaffe-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="26.314291108760937"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.274446909007805" CI_END="0.034913944761713334" CI_START="-0.5421112471857741" DF="1.0" EFFECT_SIZE="-0.25359865121203035" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-1.4570010795313282" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.6003642828999927" P_Z="0.08492800784320864" STUDIES="2" TAU2="0.0" TOTAL_1="2" TOTAL_2="2" WEIGHT="100.0" Z="1.7227817081121422">
<NAME>2 years follow up</NAME>
<IV_DATA CI_END="0.12142990978572318" CI_START="-0.5414299097857231" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15020" SE="0.1691" STUDY_ID="STD-Shumaker-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="75.77852710442755"/>
<IV_DATA CI_END="0.1962252277759302" CI_START="-0.9762252277759302" EFFECT_SIZE="-0.39" ESTIMABLE="YES" ESTIMATE="-0.39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15021" SE="0.2991" STUDY_ID="STD-Yaffe-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="24.221472895572447"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.1408335532326697" CI_START="-0.5608335532326697" DF="0.0" EFFECT_SIZE="-0.21" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-0.8512938633203859" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="1.0" P_Z="0.24072190407153649" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.1731843575418994">
<NAME>3 years follow up</NAME>
<IV_DATA CI_END="0.1408335532326697" CI_START="-0.5608335532326697" EFFECT_SIZE="-0.21" ESTIMABLE="YES" ESTIMATE="-0.21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15022" SE="0.179" STUDY_ID="STD-Shumaker-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.2063130850316904" CI_START="-0.5463130850316904" DF="0.0" EFFECT_SIZE="-0.17" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="-0.6854732268167388" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="1.0" P_Z="0.3759319562018528" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.8854166666666667">
<NAME>4 years follow up</NAME>
<IV_DATA CI_END="0.2063130850316904" CI_START="-0.5463130850316904" EFFECT_SIZE="-0.17" ESTIMABLE="YES" ESTIMATE="-0.17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15023" SE="0.192" STUDY_ID="STD-Shumaker-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.19569162640556265" CI_START="-0.7156916264055626" DF="0.0" EFFECT_SIZE="-0.26" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="-0.7084277572937692" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="5" P_CHI2="1.0" P_Z="0.26344762777849806" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.118279569892473">
<NAME>5 years follow up</NAME>
<IV_DATA CI_END="0.19569162640556265" CI_START="-0.7156916264055626" EFFECT_SIZE="-0.26" ESTIMABLE="YES" ESTIMATE="-0.26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15024" SE="0.2325" STUDY_ID="STD-Shumaker-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0876181209593368" CI_START="-0.9876181209593369" DF="0.0" EFFECT_SIZE="-0.45" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="-1.0574060648503991" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="6" P_CHI2="1.0" P_Z="0.10089303106501384" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.6405395552314985">
<NAME>6 years follow up</NAME>
<IV_DATA CI_END="0.0876181209593368" CI_START="-0.9876181209593369" EFFECT_SIZE="-0.45" ESTIMABLE="YES" ESTIMATE="-0.45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15025" SE="0.2743" STUDY_ID="STD-Shumaker-2004" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.14445874029863343" CI_START="-0.34445874029863344" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.42269379904515036" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="187" TOTAL_2="186" UNITS="" WEIGHT="100.0" Z="0.8017565590601266">
<NAME>Folstein Mini-Mental State Examination with CEE alone or CEE + MPA after 3 years</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.14445874029863343" CI_START="-0.34445874029863344" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.2" ORDER="15026" SD_1="1.1" SD_2="1.3" SE="0.12472613896321197" STUDY_ID="STD-Greenspan-2005" TOTAL_1="187" TOTAL_2="186" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>The effect of ERT/HRT versus placebo on prevention of mild cognitive impairment</NAME>
<DICH_OUTCOME CHI2="0.8555582091850378" CI_END="1.550473693561224" CI_START="0.9295419775430651" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2005125502223626" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="113" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.19046440208697402" LOG_CI_START="-0.0317309929779684" LOG_EFFECT_SIZE="0.07936670455450281" METHOD="MH" NO="1" P_CHI2="0.3549847716624075" P_Q="0.0" P_Z="0.1614618261068767" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3692" TOTAL_2="3782" WEIGHT="100.0" Z="1.4001719743380943">
<NAME>Mild cognitive impairment (based on WHIMS protocol)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9043704158352914" CI_START="0.9463570133899342" DF="0.0" EFFECT_SIZE="1.3424657534246576" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="58" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.27975142614248455" LOG_CI_START="-0.023944994998406636" LOG_EFFECT_SIZE="0.12790321557203896" NO="1" P_CHI2="1.0" P_Z="0.09875968821363099" STUDIES="1" TAU2="0.0" TOTAL_1="1463" TOTAL_2="1479" WEIGHT="50.905350695550396" Z="1.650896609754651">
<NAME>Unopposed E therapy at 5 years follow up</NAME>
<DICH_DATA CI_END="1.9043704158352914" CI_START="0.9463570133899342" EFFECT_SIZE="1.3424657534246576" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="58" LOG_CI_END="0.27975142614248455" LOG_CI_START="-0.023944994998406636" LOG_EFFECT_SIZE="0.12790321557203896" ORDER="15027" O_E="0.0" SE="0.1783927810996894" STUDY_ID="STD-Shumaker-2004" TOTAL_1="1463" TOTAL_2="1479" VAR="0.0318239843484817" WEIGHT="50.905350695550396"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5352172410600093" CI_START="0.722693247893798" DF="0.0" EFFECT_SIZE="1.053323850562691" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="55" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.18616983904319107" LOG_CI_START="-0.14104600286628008" LOG_EFFECT_SIZE="0.022561918088455542" NO="2" P_CHI2="1.0" P_Z="0.7869420392277342" STUDIES="1" TAU2="0.0" TOTAL_1="2229" TOTAL_2="2303" WEIGHT="49.094649304449604" Z="0.2702836550789609">
<NAME>Combined E and P Rx at 4 years follow up</NAME>
<DICH_DATA CI_END="1.5352172410600093" CI_START="0.7226932478937981" EFFECT_SIZE="1.053323850562691" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="55" LOG_CI_END="0.18616983904319107" LOG_CI_START="-0.14104600286628" LOG_EFFECT_SIZE="0.022561918088455542" ORDER="15028" O_E="0.0" SE="0.19220820528216367" STUDY_ID="STD-Shumaker-2003" TOTAL_1="2229" TOTAL_2="2303" VAR="0.036943994177790374" WEIGHT="49.094649304449604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>The effect of ERT/HRT versus placebo on verbal memory and language tests</NAME>
<CONT_OUTCOME CHI2="3.354027457564571" CI_END="1.4759959500301325" CI_START="-0.01631760583169206" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.7298391720992202" ESTIMABLE="YES" I2="40.370195971733594" I2_Q="48.1674666755343" ID="CMP-003.01" NO="1" P_CHI2="0.18693159249960034" P_Q="0.16483638135053802" P_Z="0.055225001757557166" Q="1.9292902273174939" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.17671744626802727" TOTALS="YES" TOTAL_1="28" TOTAL_2="29" UNITS="" WEIGHT="100.0" Z="1.9171017862863269">
<NAME>Paired Associates (intermediate recall) after HRT or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.424737230247077" CI_END="2.0684892946172537" CI_START="0.11805779599803512" DF="1.0" EFFECT_SIZE="1.0932735453076443" ESTIMABLE="YES" I2="29.81161867816281" ID="CMP-003.01.01" NO="1" P_CHI2="0.2326254979045782" P_Z="0.028003769836278444" STUDIES="2" TAU2="0.15978662823261983" TOTAL_1="16" TOTAL_2="15" WEIGHT="56.46738777147212" Z="2.1972335614661187">
<NAME>After 2 months of E2 i.m. or placebo</NAME>
<CONT_DATA CI_END="1.6548732849322478" CI_START="-0.2178931870843931" EFFECT_SIZE="0.7184900489239274" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-5.5" ORDER="15029" SD_1="6.22" SD_2="7.36" SE="0.4777553278500993" STUDY_ID="STD-Phillips-1992" TOTAL_1="10" TOTAL_2="9" WEIGHT="35.78851818699968"/>
<CONT_DATA CI_END="3.172834156618576" CI_START="0.3348709612258365" EFFECT_SIZE="1.753852558922206" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="-5.0" ORDER="15030" SD_1="3.06" SD_2="2.37" SE="0.7239835062731332" STUDY_ID="STD-Sherwin-1990" TOTAL_1="6" TOTAL_2="6" WEIGHT="20.678869584472437"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.027386333057433" CI_START="-0.5219016342424144" DF="0.0" EFFECT_SIZE="0.2527423494075093" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.02" NO="2" P_CHI2="1.0" P_Z="0.5225136058613558" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="43.53261222852788" Z="0.639475568986826">
<NAME>After 10 weeks E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="1.027386333057433" CI_START="-0.5219016342424144" EFFECT_SIZE="0.2527423494075093" ESTIMABLE="YES" MEAN_1="0.78" MEAN_2="-0.5" ORDER="15031" SD_1="5.07" SD_2="4.76" SE="0.39523378478391263" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="43.53261222852788"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.133831353721105" CI_END="1.3052359726880929" CI_START="0.01686366317856358" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.6610498179333282" ESTIMABLE="YES" I2="36.18035643094821" I2_Q="50.352396339856895" ID="CMP-003.02" NO="2" P_CHI2="0.20868795989162336" P_Q="0.15583418999200938" P_Z="0.04429669184396417" Q="2.0141959052956184" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.12276120065232428" TOTALS="YES" TOTAL_1="50" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="2.0112724025081206">
<NAME>Paired associate learning (different scoring methods immediate recall)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.878325519065392" CI_START="-0.27073823359081023" DF="0.0" EFFECT_SIZE="0.30379364273729087" ESTIMABLE="YES" I2="0.0" ID="CMP-003.02.01" NO="1" P_CHI2="1.0" P_Z="0.30003201224112186" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="18" WEIGHT="51.76398431713717" Z="1.0363647745756859">
<NAME>After 9 months with CEE + MPA or placebo</NAME>
<CONT_DATA CI_END="0.878325519065392" CI_START="-0.27073823359081023" EFFECT_SIZE="0.30379364273729087" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="0.9" ORDER="15032" SD_1="2.7" SD_2="3.3" SE="0.2931338947347682" STUDY_ID="STD-Binder-2001" TOTAL_1="34" TOTAL_2="18" WEIGHT="51.76398431713717"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1196354484254867" CI_END="1.853034275272213" CI_START="0.1871295607881046" DF="1.0" EFFECT_SIZE="1.0200819180301588" ESTIMABLE="YES" I2="10.68521442347389" ID="CMP-003.02.02" NO="2" P_CHI2="0.2899970015772686" P_Z="0.016382269857931255" STUDIES="2" TAU2="0.04331847888973678" TOTAL_1="16" TOTAL_2="15" WEIGHT="48.23601568286282" Z="2.400285926603905">
<NAME>After 2 to 3 months with E2 i.m. or placebo</NAME>
<CONT_DATA CI_END="1.6548732849322478" CI_START="-0.2178931870843931" EFFECT_SIZE="0.7184900489239274" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-5.5" ORDER="15033" SD_1="6.22" SD_2="7.36" SE="0.4777553278500993" STUDY_ID="STD-Phillips-1992" TOTAL_1="10" TOTAL_2="9" WEIGHT="30.7755218846801"/>
<CONT_DATA CI_END="2.9991848213913856" CI_START="0.23869682584960938" EFFECT_SIZE="1.6189408236204976" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-5.0" ORDER="15034" SD_1="3.06" SD_2="2.37" SE="0.7042190615021892" STUDY_ID="STD-Sherwin-1990" TOTAL_1="6" TOTAL_2="6" WEIGHT="17.46049379818272"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.2706799700200562" CI_END="0.5285431363913169" CI_START="-0.29386510476059113" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.11733901581536288" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="0.5297553751037785" P_Q="0.5297553751037785" P_Z="0.5759673189869048" Q="1.2706799700200562" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="41" UNITS="" WEIGHT="99.99999999999999" Z="0.5592848745225721">
<NAME>Paired Associate (delayed recall) after HRT or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5713129281655049" CI_START="-0.5713129281655049" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="18" WEIGHT="51.80441960419658" Z="0.0">
<NAME>After 9 months with CEE+ MPA</NAME>
<CONT_DATA CI_END="0.5713129281655049" CI_START="-0.5713129281655049" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.2" ORDER="15035" SD_1="1.0" SD_2="1.0" SE="0.2914915440650687" STUDY_ID="STD-Binder-2001" TOTAL_1="34" TOTAL_2="18" WEIGHT="51.80441960419658"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.519192473907435" CI_START="-0.33118617086073876" DF="0.0" EFFECT_SIZE="0.5940031515233481" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.02" NO="2" P_CHI2="1.0" P_Z="0.2082602295139282" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="19.753938260166066" Z="1.2583638348624715">
<NAME>After 2 months of E2 i.m. or placebo</NAME>
<CONT_DATA CI_END="1.519192473907435" CI_START="-0.33118617086073876" EFFECT_SIZE="0.5940031515233481" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-2.3" ORDER="15036" SD_1="2.42" SD_2="3.64" SE="0.47204404248336307" STUDY_ID="STD-Phillips-1992" TOTAL_1="10" TOTAL_2="9" WEIGHT="19.753938260166066"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7710457082138797" CI_START="-0.7710457082138797" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.03" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="28.441642135637345" Z="0.0">
<NAME>After 10 weeks E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.7710457082138797" CI_START="-0.7710457082138797" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="15037" SD_1="1.0" SD_2="1.29" SE="0.3933978962347216" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="28.441642135637345"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9741477087917861" CI_END="0.3853083550321766" CI_START="-0.5587335397299839" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.08671259234890362" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.32364813692811156" P_Q="0.32364813692811156" P_Z="0.7188059161129832" Q="0.9741477087917861" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="37" TOTAL_2="33" UNITS="" WEIGHT="100.0" Z="0.3600551182164903">
<NAME>Other Paired Associate tests</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8641140810493135" CI_START="-0.524632905132786" DF="0.0" EFFECT_SIZE="0.16974058795826372" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.6318561211685756" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="46.21003280659553" Z="0.4791159835780579">
<NAME>After 2 months of E2 oral + P or placebo</NAME>
<CONT_DATA CI_END="0.8641140810493135" CI_START="-0.524632905132786" EFFECT_SIZE="0.16974058795826372" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="1.0" ORDER="15038" SD_1="5.0" SD_2="6.4" SE="0.3542787003068318" STUDY_ID="STD-Linzmayer-2001" TOTAL_1="16" TOTAL_2="16" WEIGHT="46.21003280659553"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.336564898131706" CI_START="-0.9506190883368097" DF="0.0" EFFECT_SIZE="-0.3070270951025519" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.02" NO="2" P_CHI2="1.0" P_Z="0.34978547994485665" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="53.78996719340447" Z="0.9350054926179346">
<NAME>After 2 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.33656489813170587" CI_START="-0.9506190883368096" EFFECT_SIZE="-0.3070270951025519" ESTIMABLE="YES" MEAN_1="0.33" MEAN_2="1.35" ORDER="15039" SD_1="3.04" SD_2="3.5" SE="0.3283692957170791" STUDY_ID="STD-Wolf-1999" TOTAL_1="21" TOTAL_2="17" WEIGHT="53.78996719340447"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.02453036680331814" CI_END="11.370151086717936" CI_START="-2.097645336779686" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.636252874969125" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.8755429919943757" P_Q="1.0" P_Z="0.17720058760577553" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="1.3494247124653047">
<NAME>Paragraph recall (immediate) after 2 to 3 months of E2 i.m. or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.992856509798493" CI_START="-5.392856509798492" EFFECT_SIZE="5.3" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="1.5" ORDER="15040" SD_1="10.2" SD_2="13.2" SE="5.455639284263578" STUDY_ID="STD-Phillips-1992" TOTAL_1="10" TOTAL_2="9" WEIGHT="39.65935226992053"/>
<CONT_DATA CI_END="12.868851501209637" CI_START="-4.468851501209637" EFFECT_SIZE="4.2" ESTIMABLE="YES" MEAN_1="4.65" MEAN_2="0.45" ORDER="15041" SD_1="6.51" SD_2="8.66" SE="4.4229646919986445" STUDY_ID="STD-Sherwin-1990" TOTAL_1="6" TOTAL_2="6" WEIGHT="60.340647730079475"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="15.992856509798493" CI_START="-5.392856509798492" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.3" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.33131337574072495" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.9714718521232684">
<NAME>Paragraph recall (delayed) after 2 months with E2 i.m. or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.992856509798493" CI_START="-5.392856509798492" EFFECT_SIZE="5.3" ESTIMABLE="YES" MEAN_1="6.8" MEAN_2="1.5" ORDER="15042" SD_1="10.2" SD_2="13.2" SE="5.455639284263578" STUDY_ID="STD-Phillips-1992" TOTAL_1="10" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.004562505383634" CI_END="0.1852309140355187" CI_START="-0.1415901987843067" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.021820357625606003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="0.571460314230225" P_Q="0.571460314230225" P_Z="0.7935406030999607" Q="2.004562505383634" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="277" UNITS="" WEIGHT="100.0" Z="0.26171574233362926">
<NAME>Verbal Fluency (semantic memory)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="9.011765476064753E-33" CI_END="0.34995422094454876" CI_START="-0.7961480805708971" DF="0.0" EFFECT_SIZE="-0.2230969298131742" ESTIMABLE="YES" I2="100.0" ID="CMP-003.07.01" NO="1" P_CHI2="0.0" P_Z="0.4454385093058236" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="18" WEIGHT="8.131551924398234" Z="0.7630417405446398">
<NAME>After 9 months of CEE + MPA or placebo</NAME>
<CONT_DATA CI_END="0.34995422094454876" CI_START="-0.7961480805708971" EFFECT_SIZE="-0.22309692981317417" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.6" ORDER="15043" SD_1="3.2" SD_2="4.1" SE="0.29237840862274883" STUDY_ID="STD-Binder-2001" TOTAL_1="34" TOTAL_2="18" WEIGHT="8.131551924398234"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9520346117852638" CI_START="-0.335223700829223" DF="0.0" EFFECT_SIZE="0.3084054554780204" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.02" NO="2" P_CHI2="1.0" P_Z="0.3476543349806115" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="6.445977701382895" Z="0.9391488552828142">
<NAME>After 2 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.9520346117852638" CI_START="-0.335223700829223" EFFECT_SIZE="0.3084054554780204" ESTIMABLE="YES" MEAN_1="2.76" MEAN_2="1.29" ORDER="15044" SD_1="4.84" SD_2="4.44" SE="0.32838825681701705" STUDY_ID="STD-Wolf-1999" TOTAL_1="21" TOTAL_2="17" WEIGHT="6.445977701382895"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.26912581414278997" CI_START="-0.4624139184995932" DF="0.0" EFFECT_SIZE="-0.0966440521784016" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.03" NO="3" P_CHI2="1.0" P_Z="0.6045535150336523" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="57" WEIGHT="19.959257003249853" Z="0.5178634956859555">
<NAME>After 20 weeks of E2 oral or placebo</NAME>
<CONT_DATA CI_END="0.26912581414278997" CI_START="-0.4624139184995932" EFFECT_SIZE="-0.0966440521784016" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="4.0" ORDER="15045" SD_1="9.3" SD_2="9.2" SE="0.1866207079346037" STUDY_ID="STD-Almeida-2006" TOTAL_1="58" TOTAL_2="57" WEIGHT="19.959257003249853"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.534336831499241E-33" CI_END="0.26211009574088806" CI_START="-0.14182486637192143" DF="0.0" EFFECT_SIZE="0.06014261468448333" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-003.07.05" NO="5" P_CHI2="0.0" P_Z="0.5594590200867718" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="65.46321337096902" Z="0.5836452388329623">
<NAME>After 2 years low E transdermal versus placebo</NAME>
<CONT_DATA CI_END="0.26211009574088806" CI_START="-0.14182486637192143" EFFECT_SIZE="0.06014261468448332" ESTIMABLE="YES" MEAN_1="0.64" MEAN_2="0.36" ORDER="15046" SD_1="4.81" SD_2="4.47" SE="0.10304652669615282" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="65.46321337096902"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.8342851423180115" CI_END="0.1521678532816393" CI_START="-0.09728415251627673" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.027441850382681272" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="0.7986545674568372" P_Q="0.7082571688794963" P_Z="0.6663043836293615" Q="3.766375423468862" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="499" TOTAL_2="492" UNITS="" WEIGHT="99.99999999999999" Z="0.43122554374458616">
<NAME>Word list recall tests</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.06790971884914986" CI_END="0.21222755162847956" CI_START="-0.44907077686840186" DF="1.0" EFFECT_SIZE="-0.11842161261996116" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.01" NO="1" P_CHI2="0.794404902517142" P_Z="0.482704852717436" STUDIES="2" TAU2="0.0" TOTAL_1="70" TOTAL_2="71" WEIGHT="14.229156328992131" Z="0.7019588156342131">
<NAME>CVLT memory after 20 weeks with E2 oral or 10 weeks with E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.2267183610758294" CI_START="-0.5052969469256431" EFFECT_SIZE="-0.13928929292490685" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="12.7" ORDER="15048" SD_1="8.1" SD_2="9.0" SE="0.18674203040859827" STUDY_ID="STD-Almeida-2006" TOTAL_1="58" TOTAL_2="57" WEIGHT="11.612712505292814"/>
<CONT_DATA CI_END="0.7452799083312931" CI_START="-0.7968866917728428" EFFECT_SIZE="-0.025803391720774792" ESTIMABLE="YES" MEAN_1="4.89" MEAN_2="5.25" ORDER="15047" SD_1="15.15" SD_2="11.95" SE="0.3934170760964357" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.616443823699317"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0741298137297912" CI_START="-0.47796276508587276" DF="0.0" EFFECT_SIZE="0.2980835243219593" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.02" NO="2" P_CHI2="1.0" P_Z="0.4515504998479627" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.583085348021241" Z="0.7528326338646795">
<NAME>CVLT (short delay free recall) after 10 weeks E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="1.0741298137297912" CI_START="-0.47796276508587276" EFFECT_SIZE="0.2980835243219593" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="-0.01" ORDER="15049" SD_1="4.87" SD_2="3.93" SE="0.3959492600523204" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.583085348021241"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7969230273658716" CI_START="-0.7452437840087132" DF="0.0" EFFECT_SIZE="0.025839621678579245" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.03" NO="3" P_CHI2="1.0" P_Z="0.9476326269168354" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.616443106815489" Z="0.06567996080659318">
<NAME>CVLT (long delay free recall) after 10 weeks E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.7969230273658716" CI_START="-0.7452437840087132" EFFECT_SIZE="0.025839621678579245" ESTIMABLE="YES" MEAN_1="1.22" MEAN_2="1.12" ORDER="15050" SD_1="3.37" SD_2="4.04" SE="0.39341712999294876" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.616443106815489"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7710457082138797" CI_START="-0.7710457082138797" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.04" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.6166989559942397" Z="0.0">
<NAME>CVLT (recognition) after 10 weeks E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.7710457082138797" CI_START="-0.7710457082138797" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="0.0" ORDER="15051" SD_1="2.5" SD_2="0.93" SE="0.3933978962347216" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.6166989559942397"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.6846654650182153" CI_START="-0.23891703824071986" DF="0.0" EFFECT_SIZE="0.7228742133887477" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.05" NO="5" P_CHI2="1.0" P_Z="0.14072611111069724" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.6817148708216643" Z="1.4730924420390714">
<NAME>Guild memory test after 6 months of piperazine E1 or placebo</NAME>
<CONT_DATA CI_END="1.6846654650182153" CI_START="-0.23891703824071986" EFFECT_SIZE="0.7228742133887477" ESTIMABLE="YES" MEAN_1="4.89" MEAN_2="-1.22" ORDER="15052" SD_1="10.79" SD_2="3.63" SE="0.4907188393337603" STUDY_ID="STD-Hackman-1977" TOTAL_1="9" TOTAL_2="9" WEIGHT="1.6817148708216643"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.28651965898862364" CI_START="-0.11750513613319064" DF="0.0" EFFECT_SIZE="0.0845072614277165" ESTIMABLE="YES" I2="0.0" ID="CMP-003.08.06" NO="6" P_CHI2="1.0" P_Z="0.4122696699495717" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="38.120445138654716" Z="0.8199060593818116">
<NAME>Word List Memory Test after 2 years low E transdermal versus placebo</NAME>
<CONT_DATA CI_END="0.28651965898862364" CI_START="-0.11750513613319064" EFFECT_SIZE="0.0845072614277165" ESTIMABLE="YES" MEAN_1="2.23" MEAN_2="2.0" ORDER="15053" SD_1="2.76" SD_2="2.67" SE="0.10306944370118795" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="38.120445138654716"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.1340316579710005E-33" CI_END="0.17976703704339242" CI_START="-0.22408822774861142" DF="0.0" EFFECT_SIZE="-0.022160595352609506" ESTIMABLE="YES" I2="100.0" ID="CMP-003.08.07" NO="7" P_CHI2="0.0" P_Z="0.8296919214535513" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="38.15245625070051" Z="0.21509670693261845">
<NAME>Word List Recall after 2 yrs low E transdermal versus placebo</NAME>
<CONT_DATA CI_END="0.17976703704339242" CI_START="-0.22408822774861142" EFFECT_SIZE="-0.022160595352609506" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="0.78" ORDER="15054" SD_1="1.45" SD_2="1.24" SE="0.10302619537337487" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="38.15245625070051"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8732512308279354" CI_END="0.19902319273120817" CI_START="-0.8397027807362208" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.32033979400250634" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" NO="9" P_CHI2="0.6462133406782743" P_Q="0.6462133406782743" P_Z="0.22670384492864593" Q="0.8732512308279354" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="398" TOTAL_2="393" UNITS="" WEIGHT="300.0" Z="1.2088933464598302">
<NAME>Wechsler Memory Scale - Revised (logical memory - immediate recall)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="5.13388330170446" CI_START="-10.35388330170446" DF="0.0" EFFECT_SIZE="-2.61" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.01" NO="1" P_CHI2="1.0" P_Z="0.5088774309990792" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0" Z="0.6605866592183276">
<NAME>10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="5.13388330170446" CI_START="-10.35388330170446" EFFECT_SIZE="-2.61" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="2.5" ORDER="15055" SD_1="11.87" SD_2="7.36" SE="3.9510334693837352" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.579359924750952" CI_START="-0.8393599247509518" DF="0.0" EFFECT_SIZE="-0.1299999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.02" NO="2" P_CHI2="1.0" P_Z="0.7194526132812074" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.0" Z="0.35919046044173214">
<NAME>After 1 year of low E transdermal or placebo</NAME>
<CONT_DATA CI_END="0.579359924750952" CI_START="-0.8393599247509518" EFFECT_SIZE="-0.1299999999999999" ESTIMABLE="YES" MEAN_1="1.83" MEAN_2="1.96" ORDER="15056" SD_1="3.38" SD_2="3.74" SE="0.3619249794109955" STUDY_ID="STD-Yaffe-2006" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.24621901512285616" CI_START="-1.2862190151228563" DF="0.0" EFFECT_SIZE="-0.52" ESTIMABLE="YES" I2="0.0" ID="CMP-003.09.03" NO="3" P_CHI2="1.0" P_Z="0.18347098287241553" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0" Z="1.3301435383947133">
<NAME>After 2 years of low E transdermal or placebo</NAME>
<CONT_DATA CI_END="0.24621901512285616" CI_START="-1.2862190151228563" EFFECT_SIZE="-0.52" ESTIMABLE="YES" MEAN_1="2.03" MEAN_2="2.55" ORDER="15057" SD_1="3.66" SD_2="3.92" SE="0.3909352524672361" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.46527430659881613" CI_END="0.27894661417418876" CI_START="-0.750852975614668" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2359531807202396" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.10" NO="10" P_CHI2="0.7924412364241775" P_Q="0.7924412364241775" P_Z="0.36910302249153626" Q="0.46527430659881613" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="398" TOTAL_2="393" UNITS="" WEIGHT="300.0" Z="0.8981548270846756">
<NAME>Wechsler Memory Scale - Revised (logical memory - delayed recall)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.613551992617097" CI_START="-9.253551992617098" DF="0.0" EFFECT_SIZE="-0.31999999999999984" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.01" NO="1" P_CHI2="1.0" P_Z="0.9440297412231415" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0" Z="0.0702059467019547">
<NAME>After 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="8.613551992617097" CI_START="-9.253551992617098" EFFECT_SIZE="-0.31999999999999984" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="2.88" ORDER="15058" SD_1="12.87" SD_2="9.88" SE="4.558018444769299" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6319885197723664" CI_START="-0.7719885197723665" DF="0.0" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.02" NO="2" P_CHI2="1.0" P_Z="0.8450475653602147" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.0" Z="0.19544120032375015">
<NAME>After 1 year of low E transdermal or placebo</NAME>
<CONT_DATA CI_END="0.6319885197723664" CI_START="-0.7719885197723665" EFFECT_SIZE="-0.07000000000000006" ESTIMABLE="YES" MEAN_1="1.88" MEAN_2="1.95" ORDER="15059" SD_1="3.29" SD_2="3.75" SE="0.35816398939447985" STUDY_ID="STD-Yaffe-2006" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.330274803304347" CI_START="-1.1902748033043464" DF="0.0" EFFECT_SIZE="-0.4299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-003.10.03" NO="3" P_CHI2="1.0" P_Z="0.2676346625527981" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0" Z="1.1085261667087585">
<NAME>After 2 years of low E transdermal or placebo</NAME>
<CONT_DATA CI_END="0.330274803304347" CI_START="-1.1902748033043464" EFFECT_SIZE="-0.4299999999999997" ESTIMABLE="YES" MEAN_1="2.39" MEAN_2="2.82" ORDER="15060" SD_1="3.62" SD_2="3.9" SE="0.387902435606622" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="19.73857562156115" CI_START="-5.05857562156115" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.34" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.24592446072658625" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="1.1603055129579947">
<NAME>Wechsler Memory Scale - Revised (logical memory - % retained) after 10 weeks E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.73857562156115" CI_START="-5.05857562156115" EFFECT_SIZE="7.34" ESTIMABLE="YES" MEAN_1="9.34" MEAN_2="2.0" ORDER="15061" SD_1="17.71" SD_2="13.94" SE="6.325920128818454" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4457123258540879" CI_END="0.1401687317742581" CI_START="-0.06470840169763649" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.03773016503831081" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.12" NO="12" P_CHI2="0.5043781923103796" P_Q="0.5043781923103796" P_Z="0.4703597884139642" Q="0.4457123258540879" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="386" TOTAL_2="379" UNITS="" WEIGHT="200.0" Z="0.7218937843640424">
<NAME>Boston Naming Test after low E transdermal versus placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.20953018208957822" CI_START="-0.0695301820895782" DF="0.0" EFFECT_SIZE="0.07" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.01" NO="1" P_CHI2="1.0" P_Z="0.32546881195688826" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.00000000000001" Z="0.9832817306131171">
<NAME>After 1 year</NAME>
<CONT_DATA CI_END="0.20953018208957822" CI_START="-0.0695301820895782" EFFECT_SIZE="0.07" ESTIMABLE="YES" MEAN_1="0.19" MEAN_2="0.12" ORDER="15062" SD_1="0.66" SD_2="0.74" SE="0.07119017654925013" STUDY_ID="STD-Yaffe-2006" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.15087390853025953" CI_START="-0.15087390853025953" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0" Z="0.0">
<NAME>After 2 years</NAME>
<CONT_DATA CI_END="0.15087390853025953" CI_START="-0.15087390853025953" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.11" MEAN_2="0.11" ORDER="15063" SD_1="0.7" SD_2="0.79" SE="0.07697789843095774" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.23319387737180927" CI_START="-0.43319387737180926" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="-0.6322828563939185" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.5563743734147961" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.5882352941176471">
<NAME>PMA Vocabulary after 1+ years of HRT versus placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_DATA CI_END="0.23319387737180927" CI_START="-0.43319387737180926" EFFECT_SIZE="-0.1" ESTIMABLE="YES" ESTIMATE="-0.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15064" SE="0.17" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.2883895555166157" CI_START="-0.8483895555166158" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-0.28" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="-0.5400204723286072" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.3342858166703131" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.9655172413793105">
<NAME>Verbal Fluency - letter after 1+ years of HRT versus placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_DATA CI_END="0.2883895555166157" CI_START="-0.8483895555166158" EFFECT_SIZE="-0.28" ESTIMABLE="YES" ESTIMATE="-0.28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15065" SE="0.29" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.28239315706261037" CI_START="-0.4623931570626103" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-0.09" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="-0.5491458312957116" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.635725116102773" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.47368421052631576">
<NAME>Verbal Fluency - categories after 1+ years of HRT versus placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_DATA CI_END="0.28239315706261037" CI_START="-0.4623931570626103" EFFECT_SIZE="-0.09" ESTIMABLE="YES" ESTIMATE="-0.09" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15066" SE="0.19" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="11.056926229508194" CI_END="-0.03650617655709719" CI_START="-0.2372643152461814" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_SIZE="-0.1368852459016393" ESTIMABLE="YES" I2="72.86768548754767" I2_Q="72.86768548754767" ID="CMP-003.16" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="16" P_CHI2="0.011422052334021826" P_Q="0.011422052334021826" P_Z="0.0075227838371544455" Q="11.056926229508194" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="4" TOTAL_2="4" WEIGHT="400.0" Z="2.6727698685992025">
<NAME>Word list recall tests after 1+ years of HRT versus placebo (inverse variance)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.12800720309198915" CI_START="-0.9119927969080108" DF="0.0" EFFECT_SIZE="-0.52" ESTIMABLE="YES" I2="0.0" ID="CMP-003.16.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.009322376047058236" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001" Z="2.6">
<NAME>CVLT total</NAME>
<IV_DATA CI_END="-0.12800720309198915" CI_START="-0.9119927969080108" EFFECT_SIZE="-0.52" ESTIMABLE="YES" ESTIMATE="-0.52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15067" SE="0.2" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.20679711876320434" CI_START="-0.10679711876320434" DF="0.0" EFFECT_SIZE="0.05" ESTIMABLE="YES" I2="0.0" ID="CMP-003.16.02" LOG_CI_END="-0.6844555164192865" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3010299956639813" NO="2" P_CHI2="1.0" P_Z="0.5319710616574185" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.625">
<NAME>CVLT Interference</NAME>
<IV_DATA CI_END="0.20679711876320434" CI_START="-0.10679711876320434" EFFECT_SIZE="0.05" ESTIMABLE="YES" ESTIMATE="0.05" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15068" SE="0.08" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.04400360154599456" CI_START="-0.4359963984540054" DF="0.0" EFFECT_SIZE="-0.24" ESTIMABLE="YES" I2="0.0" ID="CMP-003.16.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="1.0" P_Z="0.016395071848725462" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001" Z="2.4">
<NAME>CVLT short delay</NAME>
<IV_DATA CI_END="-0.04400360154599456" CI_START="-0.4359963984540054" EFFECT_SIZE="-0.24" ESTIMABLE="YES" ESTIMATE="-0.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15069" SE="0.1" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.03400360154599458" CI_START="-0.42599639845400544" DF="0.0" EFFECT_SIZE="-0.23" ESTIMABLE="YES" I2="0.0" ID="CMP-003.16.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="4" P_CHI2="1.0" P_Z="0.021448220043083614" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001" Z="2.3">
<NAME>CVLT long delay</NAME>
<IV_DATA CI_END="-0.03400360154599458" CI_START="-0.42599639845400544" EFFECT_SIZE="-0.23" ESTIMABLE="YES" ESTIMATE="-0.23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15070" SE="0.1" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.00000000000001"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>The effect of ERT/HRT versus placebo on visual memory</NAME>
<CONT_OUTCOME CHI2="15.085221555913417" CI_END="0.16357010750827974" CI_START="-0.09185135820284687" CI_STUDY="95" CI_TOTAL="95" DF="13.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.035859374652716436" ESTIMABLE="YES" I2="13.822942859569796" I2_Q="13.822942859569796" ID="CMP-004.01" NO="1" P_CHI2="0.30206290042749795" P_Q="0.30206290042749795" P_Z="0.5820928645466865" Q="15.085221555913417" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.007689227994482347" TOTALS="YES" TOTAL_1="679" TOTAL_2="663" UNITS="" WEIGHT="100.0" Z="0.550330275740729">
<NAME>Visuo(spatial) memory tests</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.167138315092242" CI_START="-0.6436220067194449" DF="0.0" EFFECT_SIZE="0.26175815418639864" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" NO="1" P_CHI2="1.0" P_Z="0.5709498334896512" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.9205193267368135" Z="0.5666531883708659">
<NAME>VRT immediate recall after 2 months of E2 or placebo</NAME>
<CONT_DATA CI_END="1.167138315092242" CI_START="-0.6436220067194447" EFFECT_SIZE="0.26175815418639864" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-1.2" ORDER="15071" SD_1="3.41" SD_2="4.6" SE="0.46193714172676975" STUDY_ID="STD-Phillips-1992" TOTAL_1="10" TOTAL_2="9" WEIGHT="1.9205193267368135"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0186086424476832" CI_START="-0.2828656460301004" DF="0.0" EFFECT_SIZE="0.36787149820879145" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" NO="2" P_CHI2="1.0" P_Z="0.26786307356222827" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="3.6004747666218737" Z="1.1079971288120152">
<NAME>Paired objects recall (BETAM) after 3 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="1.0186086424476832" CI_START="-0.2828656460301004" EFFECT_SIZE="0.36787149820879145" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="-0.4" ORDER="15072" SD_1="3.65" SD_2="4.32" SE="0.3320148479114021" STUDY_ID="STD-Duka-2000" TOTAL_1="19" TOTAL_2="18" WEIGHT="3.6004747666218737"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5430616631534647" CI_START="-0.736662041390668" DF="0.0" EFFECT_SIZE="-0.09680018911860169" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.03" NO="3" P_CHI2="1.0" P_Z="0.7668412921016143" STUDIES="1" TAU2="0.0" TOTAL_1="21" TOTAL_2="17" WEIGHT="3.7155988117541856" Z="0.29650913505069404">
<NAME>Visuospatial map recall after 2 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.5430616631534647" CI_START="-0.736662041390668" EFFECT_SIZE="-0.09680018911860169" ESTIMABLE="YES" MEAN_1="0.24" MEAN_2="0.77" ORDER="15073" SD_1="4.4" SD_2="6.36" SE="0.3264661276019432" STUDY_ID="STD-Wolf-1999" TOTAL_1="21" TOTAL_2="17" WEIGHT="3.7155988117541856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.35433856799142" CI_START="-1.0432360351054741" DF="0.0" EFFECT_SIZE="-0.34444873355702704" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.04" NO="4" P_CHI2="1.0" P_Z="0.33398792727465754" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="3.1496181463135753" Z="0.9661124505213994">
<NAME>Benton Visual Retention Test (# correct) after 2 months of E2 oral or placebo</NAME>
<CONT_DATA CI_END="0.35433856799142" CI_START="-1.0432360351054741" EFFECT_SIZE="-0.34444873355702704" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="1.0" ORDER="15074" SD_1="2.83" SD_2="2.83" SE="0.3565306847780837" STUDY_ID="STD-Linzmayer-2001" TOTAL_1="16" TOTAL_2="16" WEIGHT="3.1496181463135753"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.1604002715250927" CI_START="-1.0213854238225744" DF="0.0" EFFECT_SIZE="0.0695074238512591" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.05" NO="5" P_CHI2="1.0" P_Z="0.900617573415728" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="6" WEIGHT="1.3373426627411646" Z="0.12488123622510015">
<NAME>Visual immediate recall (drop in errors) after 1 month of CEE or placebo</NAME>
<CONT_DATA CI_END="1.1604002715250927" CI_START="-1.0213854238225744" EFFECT_SIZE="0.0695074238512591" ESTIMABLE="YES" MEAN_1="2.73" MEAN_2="2.41" ORDER="15075" SD_1="3.97" SD_2="4.63" SE="0.5565882109460465" STUDY_ID="STD-Janowsky-2000" TOTAL_1="7" TOTAL_2="6" WEIGHT="1.3373426627411646"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7948583645913271" CI_START="0.05526180148256521" DF="0.0" EFFECT_SIZE="0.42506008303694615" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.06" NO="6" P_CHI2="1.0" P_Z="0.0242681997996078" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="57" WEIGHT="9.808266564133437" Z="2.2528564776348396">
<NAME>Visual memory for faces (total score) after 20 weeks E2 oral or placebo</NAME>
<CONT_DATA CI_END="0.7948583645913271" CI_START="0.05526180148256521" EFFECT_SIZE="0.42506008303694615" ESTIMABLE="YES" MEAN_1="4.5" MEAN_2="2.7" ORDER="15076" SD_1="4.4" SD_2="4.0" SE="0.18867605959665718" STUDY_ID="STD-Almeida-2006" TOTAL_1="58" TOTAL_2="57" WEIGHT="9.808266564133437"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4287728790143108" CI_START="-0.30251362501376133" DF="0.0" EFFECT_SIZE="0.06312962700027473" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.07" NO="7" P_CHI2="1.0" P_Z="0.7350656513306131" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="57" WEIGHT="9.991881071130125" Z="0.33839485508469364">
<NAME>Visual memory for faces (delayed recall) after 20 weeks E2 oral or placebo</NAME>
<CONT_DATA CI_END="0.4287728790143108" CI_START="-0.30251362501376133" EFFECT_SIZE="0.06312962700027473" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="3.6" ORDER="15077" SD_1="5.1" SD_2="4.3" SE="0.18655610761125377" STUDY_ID="STD-Almeida-2006" TOTAL_1="58" TOTAL_2="57" WEIGHT="9.991881071130125"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6870730306647208" CI_START="-0.04882730662784118" DF="0.0" EFFECT_SIZE="0.3191228620184398" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.08" NO="8" P_CHI2="1.0" P_Z="0.08915442838420426" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="57" WEIGHT="9.889351859240834" Z="1.699875063247397">
<NAME>Visuospatial Organisation (Block Design) after 20 weeks of E2 oral or placebo</NAME>
<CONT_DATA CI_END="0.6870730306647208" CI_START="-0.04882730662784118" EFFECT_SIZE="0.3191228620184398" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="3.2" ORDER="15078" SD_1="3.0" SD_2="5.4" SE="0.18773312752102841" STUDY_ID="STD-Almeida-2006" TOTAL_1="58" TOTAL_2="57" WEIGHT="9.889351859240834"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.9232673645188458E-32" CI_END="0.293735305962097" CI_START="-1.2753208594205723" DF="0.0" EFFECT_SIZE="-0.49079277672923766" ESTIMABLE="YES" I2="100.0" ID="CMP-004.01.09" NO="9" P_CHI2="0.0" P_Z="0.22014846306595137" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.5286001265647933" Z="1.22613350303762">
<NAME>Rey-Osterreith (delayed recall) after 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.29373530596209707" CI_START="-1.2753208594205723" EFFECT_SIZE="-0.4907927767292376" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="6.62" ORDER="15079" SD_1="10.53" SD_2="7.72" SE="0.4002767851244166" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.5286001265647933"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.34831092684050263" CI_START="-1.2148340890920828" DF="0.0" EFFECT_SIZE="-0.4332615811257901" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.10" NO="10" P_CHI2="1.0" P_Z="0.2772586695583118" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.546876704369785" Z="1.0864981639400888">
<NAME>Wechsler Memory Scale - Revised (visual reproduction immediate) after 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.34831092684050263" CI_START="-1.2148340890920828" EFFECT_SIZE="-0.4332615811257901" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="1.89" ORDER="15080" SD_1="5.06" SD_2="5.33" SE="0.39876881112675383" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.546876704369785"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8022045413009242" CI_START="-0.7399961206204813" DF="0.0" EFFECT_SIZE="0.031104210340221507" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.11" NO="11" P_CHI2="1.0" P_Z="0.9369849612869003" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.6132276790040474" Z="0.07905992201875911">
<NAME>Wechsler Memory Scale - Revised (visual reproduction delayed) after 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.8022045413009242" CI_START="-0.7399961206204813" EFFECT_SIZE="0.031104210340221507" ESTIMABLE="YES" MEAN_1="2.66" MEAN_2="2.37" ORDER="15081" SD_1="11.27" SD_2="6.56" SE="0.39342576549520486" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.6132276790040474"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.23394257996568557" CI_START="-1.3424571170388582" DF="0.0" EFFECT_SIZE="-0.5542572685365863" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.12" NO="12" P_CHI2="1.0" P_Z="0.16813087503969673" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.5061632042621795" Z="1.3782345766311364">
<NAME>Wechsler Memory Scale - Revised (visual reproduction recognition) after 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.23394257996568557" CI_START="-1.3424571170388582" EFFECT_SIZE="-0.5542572685365863" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="0.25" ORDER="15082" SD_1="1.61" SD_2="0.7" SE="0.40215016945183263" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="2.5061632042621795"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.18460318068252646" CI_START="-0.21924721310996292" DF="0.0" EFFECT_SIZE="-0.01732201621371823" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.13" NO="13" P_CHI2="1.0" P_Z="0.8664777183921848" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="23.196773373969627" Z="0.16813418256044302">
<NAME>Brief Visuospatial Memory Test (immediate) after 2 years low E transdermal versus placebo</NAME>
<CONT_DATA CI_END="0.18460318068252646" CI_START="-0.21924721310996292" EFFECT_SIZE="-0.01732201621371823" ESTIMABLE="YES" MEAN_1="3.69" MEAN_2="3.78" ORDER="15083" SD_1="5.2" SD_2="5.17" SE="0.1030249527486244" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="23.196773373969627"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16781641316325244" CI_START="-0.2360560126032147" DF="0.0" EFFECT_SIZE="-0.03411979971998113" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.14" NO="14" P_CHI2="1.0" P_Z="0.7405222029095372" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="23.19530570315756" Z="0.3311618934319197">
<NAME>Brief Visuospatial Memory Test (delayed) after 2 years low E transdermal versus placebo</NAME>
<CONT_DATA CI_END="0.16781641316325244" CI_START="-0.2360560126032147" EFFECT_SIZE="-0.03411979971998113" ESTIMABLE="YES" MEAN_1="0.75" MEAN_2="0.81" ORDER="15084" SD_1="1.69" SD_2="1.82" SE="0.10303057325342743" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="23.19530570315756"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="-0.054403961700594056" CI_START="-0.485596038299406" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-0.27" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.014106282946891468" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.4545454545454546">
<NAME>Visuospatial memory tests (inverse variance)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="-0.054403961700594056" CI_START="-0.485596038299406" DF="0.0" EFFECT_SIZE="-0.27" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="1.0" P_Z="0.014106282946891468" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="2.4545454545454546">
<NAME>Benton Visual Retention Test after 1+ years of HRT versus placebo</NAME>
<IV_DATA CI_END="-0.054403961700594056" CI_START="-0.485596038299406" EFFECT_SIZE="-0.27" ESTIMABLE="YES" ESTIMATE="-0.27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15085" SE="0.11" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>The effect of ERT/HRT versus placebo on speed tests, attention and manual dexterity</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.04663272933967" CI_START="-24.04663272933967" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12872001159247162" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.5191688037056366">
<NAME>Test of simple speed of information processing</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="3.04663272933967" CI_START="-24.04663272933967" DF="0.0" EFFECT_SIZE="-10.5" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.01" NO="1" P_CHI2="1.0" P_Z="0.12872001159247162" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="18" WEIGHT="100.0" Z="1.5191688037056366">
<NAME>TMT-A after 9 months of CEE + MPA or placebo</NAME>
<CONT_DATA CI_END="3.04663272933967" CI_START="-24.04663272933967" EFFECT_SIZE="-10.5" ESTIMABLE="YES" MEAN_1="-7.5" MEAN_2="3.0" ORDER="15086" SD_1="25.0" SD_2="23.0" SE="6.911674314525053" STUDY_ID="STD-Binder-2001" TOTAL_1="34" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3972778692933712" CI_END="0.28281312599532005" CI_START="-0.306240081001515" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.011713477503097484" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.02" NO="2" P_CHI2="0.924610828513506" P_Q="0.909756499580256" P_Z="0.9378687841169097" Q="1.0002608259227994" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="91" UNITS="" WEIGHT="100.0" Z="0.07794879568464715">
<NAME>Tests of other information processing</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5451370360833929" CI_START="-0.7450988855647038" DF="0.0" EFFECT_SIZE="-0.09998092474065541" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.02" NO="2" P_CHI2="1.0" P_Z="0.7613131292704693" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="20.843506956404145" Z="0.3037568685615014">
<NAME>Stroop (digits) after 3 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.5451370360833929" CI_START="-0.7450988855647038" EFFECT_SIZE="-0.09998092474065541" ESTIMABLE="YES" MEAN_1="-16.7" MEAN_2="-3.65" ORDER="15087" SD_1="132.0" SD_2="123.0" SE="0.32914786491622117" STUDY_ID="STD-Duka-2000" TOTAL_1="19" TOTAL_2="18" WEIGHT="20.843506956404145"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.39701704337057186" CI_END="0.37976952578956086" CI_START="-0.6072373048420502" DF="1.0" EFFECT_SIZE="-0.11373388952624468" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.03" NO="3" P_CHI2="0.5286342181316748" P_Z="0.6514868210864461" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="35.617934675914036" Z="0.45169763850661143">
<NAME>Stroop (colour) after 2 - 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.8482382697101459" CI_START="-0.6945200720719983" EFFECT_SIZE="0.07685909881907386" ESTIMABLE="YES" MEAN_1="1.78" MEAN_2="0.5" ORDER="15089" SD_1="20.88" SD_2="10.55" SE="0.39356803338000723" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="14.578513483313762"/>
<CONT_DATA CI_END="0.3963088655033663" CI_START="-0.8879058166449177" EFFECT_SIZE="-0.24579847557077572" ESTIMABLE="YES" MEAN_1="-3.05" MEAN_2="-1.29" ORDER="15088" SD_1="7.51" SD_2="6.33" SE="0.32761180620613584" STUDY_ID="STD-Wolf-1999" TOTAL_1="21" TOTAL_2="17" WEIGHT="21.039421192600276"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8981659428509573" CI_START="-0.6457234842070895" DF="0.0" EFFECT_SIZE="0.12622122932193394" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.05" NO="5" P_CHI2="1.0" P_Z="0.7486081994247431" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="14.557160268028827" Z="0.32047510556086">
<NAME>Stroop (word) after 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.8981659428509573" CI_START="-0.6457234842070895" EFFECT_SIZE="0.12622122932193394" ESTIMABLE="YES" MEAN_1="-0.66" MEAN_2="-1.87" ORDER="15090" SD_1="7.45" SD_2="10.59" SE="0.39385658084435465" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="14.557160268028827"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6914933686591138" CI_START="-0.8513190090804581" DF="0.0" EFFECT_SIZE="-0.07991282021067214" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.08" NO="8" P_CHI2="1.0" P_Z="0.8391038318566759" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="14.577492296097658" Z="0.20303991823739514">
<NAME>Pegboard (dominant hand) after 10 weeks E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="0.6914933686591138" CI_START="-0.8513190090804581" EFFECT_SIZE="-0.07991282021067214" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-0.17" ORDER="15091" SD_1="29.22" SD_2="13.62" SE="0.393581818316326" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="14.577492296097658"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0739511964021637" CI_START="-0.4781298250811219" DF="0.0" EFFECT_SIZE="0.2979106856605209" ESTIMABLE="YES" I2="0.0" ID="CMP-005.02.09" NO="9" P_CHI2="1.0" P_Z="0.4518095190545446" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="14.403905803555334" Z="0.7524017192688058">
<NAME>Pegboard (non-dominant hand) after 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="1.0739511964021637" CI_START="-0.4781298250811219" EFFECT_SIZE="0.2979106856605209" ESTIMABLE="YES" MEAN_1="2.33" MEAN_2="-5.0" ORDER="15092" SD_1="30.72" SD_2="15.8" SE="0.3959463116990676" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="14.403905803555334"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="1.3374513502689138E-32" CI_END="0.17759783907240323" CI_START="-0.057597839072403255" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.05999999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.7505623228177811" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.2218487496163564" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.31731052126128767" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.9999999999999999">
<NAME>Attention and working memory tests after 1+ year HRT versus placebo (inverse variance)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.3374513502689138E-32" CI_END="0.17759783907240323" CI_START="-0.057597839072403255" DF="0.0" EFFECT_SIZE="0.05999999999999999" ESTIMABLE="YES" I2="100.0" ID="CMP-005.03.01" LOG_CI_END="-0.7505623228177811" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.2218487496163564" NO="1" P_CHI2="0.0" P_Z="0.31731052126128767" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.9999999999999999">
<NAME>Digits forward</NAME>
<IV_DATA CI_END="0.17759783907240323" CI_START="-0.05759783907240325" EFFECT_SIZE="0.06" ESTIMABLE="YES" ESTIMATE="0.06" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15093" SE="0.06" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.005479452054794521" CI_END="0.27105542391919957" CI_START="-0.2468910403575557" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_SIZE="0.012082191780821915" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-0.5669418979033629" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.9178542749886363" NO="4" P_CHI2="0.9409918287665434" P_Q="0.9409918287665434" P_Z="0.9271425241635719" Q="0.005479452054794521" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="2" TOTAL_2="2" WEIGHT="200.0" Z="0.09144057302441004">
<NAME>Fine Motor Speed after 1+ yrs of HRT versus placebo (inverse variance)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.4115924367534114" CI_START="-0.4115924367534114" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-0.38553261424594437" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.0">
<NAME>Finger tapping dominant</NAME>
<IV_DATA CI_END="0.4115924367534114" CI_START="-0.4115924367534114" EFFECT_SIZE="0.0" ESTIMABLE="YES" ESTIMATE="0.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15094" SE="0.21" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.3531938773718093" CI_START="-0.31319387737180926" DF="0.0" EFFECT_SIZE="0.02" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-0.451986833539217" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6989700043360187" NO="2" P_CHI2="1.0" P_Z="0.9063473162998039" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.11764705882352941">
<NAME>Finger tapping non dominant</NAME>
<IV_DATA CI_END="0.3531938773718093" CI_START="-0.31319387737180926" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15095" SE="0.17" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<CONT_OUTCOME CHI2="0.7365931855631547" CI_END="1.3075957775836031" CI_START="-1.3956264324567675" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.04401532743658226" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-005.05" NO="5" P_CHI2="0.8645649770856579" P_Q="0.5507906816197865" P_Z="0.9491084654878672" Q="0.3559029989641935" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="47" UNITS="" WEIGHT="99.99999999999997" Z="0.06382638927944484">
<NAME>Tests of general information processing speed and recognition</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="7.053124697273782" CI_START="-13.273124697273781" DF="0.0" EFFECT_SIZE="-3.11" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.01" NO="1" P_CHI2="1.0" P_Z="0.5486627663722673" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.7686788976990375" Z="0.5997651483657048">
<NAME>Wechsler Adult Intelligence Scale - Revised (Digit Symbol) after 10 weeks of E2 transdermal or placebo</NAME>
<CONT_DATA CI_END="7.053124697273782" CI_START="-13.273124697273781" EFFECT_SIZE="-3.11" ESTIMABLE="YES" MEAN_1="-0.23" MEAN_2="2.88" ORDER="15096" SD_1="14.91" SD_2="10.82" SE="5.185362984952382" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="1.7686788976990375"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.3806901865989612" CI_END="1.3749133387727532" CI_START="-1.352536389835231" DF="2.0" EFFECT_SIZE="0.011188474468761235" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" NO="2" P_CHI2="0.8266738612510812" P_Z="0.9871703870975744" STUDIES="3" TAU2="0.0" TOTAL_1="32" TOTAL_2="33" WEIGHT="98.23132110230094" Z="0.01608022818584444">
<NAME>Wechsler Adult Intelligence Scale - Revised (Digit Span) after 9-10 weeks of E2 or placebo</NAME>
<CONT_DATA CI_END="4.1978073131091564" CI_START="-3.6978073131091564" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.25" ORDER="15097" SD_1="4.02" SD_2="6.16" SE="2.0142244164938523" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="11.721727157625072"/>
<CONT_DATA CI_END="1.3647884602912788" CI_START="-1.7647884602912787" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.3" ORDER="15099" SD_1="1.84" SD_2="1.64" SE="0.7983761296810198" STUDY_ID="STD-Phillips-1992" TOTAL_1="10" TOTAL_2="9" WEIGHT="74.6091742310492"/>
<CONT_DATA CI_END="5.01805575637732" CI_START="-2.8180557563773196" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="-0.6" ORDER="15098" SD_1="4.47" SD_2="4.47" SE="1.9990447718848119" STUDY_ID="STD-Sherwin-1988" TOTAL_1="10" TOTAL_2="10" WEIGHT="11.90041971362668"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>The effect of ERT/HRT on event related potentials</NAME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>The effect of ERT/HRT versus placebo on tests of mental rotations</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="273.07684521313763" CI_START="-442.2768452131377" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-84.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6429464414220103" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.4635831346401011">
<NAME>Mental Rotations time (120 degrees only) after 3 weeks of E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="273.07684521313763" CI_START="-442.2768452131377" EFFECT_SIZE="-84.6" ESTIMABLE="YES" MEAN_1="-102.7" MEAN_2="-18.1" ORDER="15100" SD_1="673.1" SD_2="412.6" SE="182.4915396580993" STUDY_ID="STD-Duka-2000" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.2481479651417744" CI_START="-1.7881479651417744" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.73" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5699094103712046" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="21" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="0.5681849234120305">
<NAME>Mental Rotations number after 2 weeks of E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.2481479651417744" CI_START="-1.7881479651417744" EFFECT_SIZE="0.73" ESTIMABLE="YES" MEAN_1="1.91" MEAN_2="1.18" ORDER="15101" SD_1="4.75" SD_2="3.13" SE="1.2847929783427676" STUDY_ID="STD-Wolf-1999" TOTAL_1="21" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.9819747891780378" CI_START="-1.761974789178038" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="-0.39" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-0.007899661970087287" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5774298305726874" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="0.5571428571428572">
<NAME>Card rotations after 1+ year of HRT versus placebo (inverse variance)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_DATA CI_END="0.9819747891780378" CI_START="-1.761974789178038" EFFECT_SIZE="-0.39" ESTIMABLE="YES" ESTIMATE="-0.39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15102" SE="0.7" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>The effect of ERT/HRT versus placebo on accuracy</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.284113000784181" CI_START="4.715886999215819" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="5.291493577040321E-20" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.00000000000001" Z="9.157904249905478">
<NAME>Clerical speed and accuracy (# correct) after 3 months of E2 i.m. or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.284113000784181" CI_START="4.715886999215819" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="0.0" ORDER="15103" SD_1="1.47" SD_2="1.46" SE="0.6551717332119876" STUDY_ID="STD-Sherwin-1988" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0571312928165505" CI_START="-0.0571312928165505" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="34" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Letter Cancellation (# correct) after 9 months of CEE or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0571312928165505" CI_START="-0.0571312928165505" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.03" MEAN_2="0.03" ORDER="15104" SD_1="0.1" SD_2="0.1" SE="0.029149154406506877" STUDY_ID="STD-Binder-2001" TOTAL_1="34" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.1406337579579375" CI_START="-5.540633757957938" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8046843021705029" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.2472893479558144">
<NAME>Random number generation after 3 weeks of E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.1406337579579375" CI_START="-5.540633757957938" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.0" ORDER="15105" SD_1="12.33" SD_2="6.66" SE="3.2350766687408785" STUDY_ID="STD-Duka-2000" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>The effect of ERT/HRT versus placebo on executive function</NAME>
<CONT_OUTCOME CHI2="9.954351176995313E-33" CI_END="0.7204903986732274" CI_START="-1.4604903986732272" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.36999999999999994" ESTIMABLE="YES" I2="99.99999999999999" I2_Q="0.0" ID="CMP-009.01" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.506044304086092" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.6650096829482741">
<NAME>Wisconsin Card Sorting Test (categories) after 10 weeks E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7204903986732273" CI_START="-1.4604903986732274" EFFECT_SIZE="-0.37" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="0.25" ORDER="15106" SD_1="1.52" SD_2="1.28" SE="0.5563828760502113" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.140509571587584E-33" CI_END="16.666686217586445" CI_START="-10.386686217586448" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1399999999999997" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-009.02" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.6491281381278617" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.4549737321070107">
<NAME>Wisconsin Card Sorting Test (perseverative responses) after 10 weeks E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.666686217586445" CI_START="-10.386686217586446" EFFECT_SIZE="3.14" ESTIMABLE="YES" MEAN_1="-3.11" MEAN_2="-6.25" ORDER="15107" SD_1="19.87" SD_2="14.36" SE="6.901497335809852" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.269836907600656" CI_START="-21.329836907600658" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.03" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.647977308651235" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.45657394921602745">
<NAME>Wisconsin Card Sorting Test (% conceptual level responses) after 10 weeks E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.269836907600656" CI_START="-21.329836907600658" EFFECT_SIZE="-4.03" ESTIMABLE="YES" MEAN_1="0.13" MEAN_2="4.16" ORDER="15108" SD_1="23.69" SD_2="20.88" SE="8.826609592859645" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.735968317549494E-33" CI_END="4.282607925168861" CI_START="-6.162607925168862" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9400000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-009.04" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.7242627793232067" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.3527674625140623">
<NAME>Weschler Adult Intelligence Scale - Revised (picture arrangement) after 10 weeks E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.282607925168861" CI_START="-6.162607925168862" EFFECT_SIZE="-0.94" ESTIMABLE="YES" MEAN_1="0.56" MEAN_2="1.5" ORDER="15109" SD_1="8.07" SD_2="4.84" SE="2.664644843662499" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.1406337579579375" CI_START="-5.540633757957938" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.8046843021705029" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="0.2472893479558144">
<NAME>Tower of London after 3 weeks of E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.1406337579579375" CI_START="-5.540633757957938" EFFECT_SIZE="0.8" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.0" ORDER="15110" SD_1="12.33" SD_2="6.66" SE="3.2350766687408785" STUDY_ID="STD-Duka-2000" TOTAL_1="19" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8629375492289805E-30" CI_END="8.075408067099673" CI_START="5.524591932900325" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.799999999999999" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-009.06" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="1.46839551631337E-25" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="10.449796765971678">
<NAME>Abstract reasoning (DAT) after 3 months of IM E2 or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.075408067099675" CI_START="5.524591932900325" EFFECT_SIZE="6.8" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="-2.8" ORDER="15111" SD_1="1.44" SD_2="1.47" SE="0.6507303589045158" STUDY_ID="STD-Sherwin-1988" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.331277559962096" CI_START="-13.311277559962097" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.9899999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.5701792758128796" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.5677874933339437">
<NAME>Controlled Word Association Test (COWAT) after 10 weeks E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.331277559962096" CI_START="-13.311277559962097" EFFECT_SIZE="-2.9899999999999998" ESTIMABLE="YES" MEAN_1="-0.11" MEAN_2="2.88" ORDER="15112" SD_1="14.97" SD_2="11.26" SE="5.266054703747118" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.787188753830431E-33" CI_END="18.46984909937381" CI_START="-31.849849099373813" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.690000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-009.08" NO="8" P_CHI2="0.0" P_Q="1.0" P_Z="0.6022594132450486" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.5211541215841118">
<NAME>Stroop test (interference time) after 10 weeks of E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.46984909937381" CI_START="-31.849849099373813" EFFECT_SIZE="-6.69" ESTIMABLE="YES" MEAN_1="-12.56" MEAN_2="-5.87" ORDER="15113" SD_1="38.39" SD_2="24.24" SE="12.836893584694153" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4869429233448574" CI_START="-1.4269429233448574" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.47000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.3357326684248493" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.9626311562177206">
<NAME>Stroop (interference errors) after 10 weeks of E2 transdermal or placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4869429233448573" CI_START="-1.4269429233448574" EFFECT_SIZE="-0.47000000000000003" ESTIMABLE="YES" MEAN_1="-0.34" MEAN_2="0.13" ORDER="15114" SD_1="1.66" SD_2="0.35" SE="0.4882451569993637" STUDY_ID="STD-Dunkin-2005" TOTAL_1="12" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3441367231816717" CI_END="2.936466574089521" CI_START="-10.304963531375005" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.6842484786427416" ESTIMABLE="YES" I2="40.19383280187288" I2_Q="40.19383280187288" ID="CMP-009.10" NO="10" P_CHI2="0.18785831966035604" P_Q="0.18785831966035604" P_Z="0.27541952616454346" Q="3.3441367231816717" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="420" TOTAL_2="397" UNITS="" WEIGHT="300.0" Z="1.0906668344314672">
<NAME>Trails B with either CEE + MPA or low E transdermal versus placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.22214010569947" CI_START="-34.42214010569947" DF="0.0" EFFECT_SIZE="-16.1" ESTIMABLE="YES" I2="0.0" ID="CMP-009.10.01" NO="1" P_CHI2="1.0" P_Z="0.08502311078339059" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="18" WEIGHT="100.00000000000001" Z="1.7222562413044165">
<NAME>After 9 months</NAME>
<CONT_DATA CI_END="2.22214010569947" CI_START="-34.42214010569947" EFFECT_SIZE="-16.1" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="5.8" ORDER="15115" SD_1="34.0" SD_2="31.0" SE="9.348202441586771" STUDY_ID="STD-Binder-2001" TOTAL_1="34" TOTAL_2="18" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="4.076935443858856" CI_START="-16.116935443858857" DF="0.0" EFFECT_SIZE="-6.02" ESTIMABLE="YES" I2="0.0" ID="CMP-009.10.02" NO="2" P_CHI2="1.0" P_Z="0.2425766485643408" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.0" Z="1.168570726487856">
<NAME>After 1 year</NAME>
<CONT_DATA CI_END="4.076935443858858" CI_START="-16.116935443858857" EFFECT_SIZE="-6.02" ESTIMABLE="YES" MEAN_1="-17.13" MEAN_2="-11.11" ORDER="15116" SD_1="46.52" SD_2="54.63" SE="5.151592337156292" STUDY_ID="STD-Yaffe-2006" TOTAL_1="194" TOTAL_2="194" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.277197090696266" CI_START="-7.6971970906962675" DF="0.0" EFFECT_SIZE="2.289999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-009.10.03" NO="3" P_CHI2="1.0" P_Z="0.6531379942811806" STUDIES="1" TAU2="0.0" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0" Z="0.44940712432499075">
<NAME>After 2 years</NAME>
<CONT_DATA CI_END="12.277197090696266" CI_START="-7.6971970906962675" EFFECT_SIZE="2.289999999999999" ESTIMABLE="YES" MEAN_1="-13.33" MEAN_2="-15.62" ORDER="15117" SD_1="48.51" SD_2="50.36" SE="5.095602352631988" STUDY_ID="STD-Yaffe-2006" TOTAL_1="192" TOTAL_2="185" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.19759783907240325" CI_START="-0.037597839072403244" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_SIZE="0.08" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-009.11" LOG_CI_END="-0.7042178091616631" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.0969100130080565" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.1824224394582603" Q="0.0" RANDOM="NO" SCALE="1.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.3333333333333335">
<NAME>Digits Backward after 1+ year HRT versus placebo</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<EFFECT_MEASURE>WMD</EFFECT_MEASURE>
<IV_DATA CI_END="0.19759783907240325" CI_START="-0.037597839072403244" EFFECT_SIZE="0.08" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="15118" SE="0.06" STUDY_ID="STD-Resnick-2006" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>